| Year |
Citation |
Score |
| 2024 |
Kumar S, Rajkumar SV, Jevremovic D, Kyle RA, Shifrin Y, Nguyen M, Husain Z, Alikhah A, Jafari A, Mai S, Anderson K, Louis S. Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma. American Journal of Hematology. PMID 38747543 DOI: 10.1002/ajh.27364 |
0.302 |
|
| 2024 |
Abdallah NH, Lakshman A, Kumar SK, Cook J, Binder M, Kapoor P, Dispenzieri A, Gertz MA, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Lin Y, Kourelis T, Warsame R, ... ... Rajkumar SV, et al. Mode of progression in smoldering multiple myeloma: a study of 406 patients. Blood Cancer Journal. 14: 9. PMID 38228628 DOI: 10.1038/s41408-024-00980-5 |
0.327 |
|
| 2023 |
Rajkumar SV, Bergsagel PL, Kumar S. Smoldering Multiple Myeloma: Observation Versus Control Versus Cure. Hematology/Oncology Clinics of North America. PMID 38158241 DOI: 10.1016/j.hoc.2023.12.001 |
0.311 |
|
| 2023 |
Rajkumar S, Abdallah N, Lakshman A, Kumar S, Cook J, Binder M, Kapoor P, Dispenzieri A, Gertz M, Lacy M, Hayman S, Buadi F, Dingli D, Lin Y, Kourelis T, et al. Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients. Research Square. PMID 37961238 DOI: 10.21203/rs.3.rs-3378634/v1 |
0.327 |
|
| 2023 |
Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Cook J, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, ... ... Rajkumar SV, et al. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy. Blood Advances. 7: 4371-4380. PMID 37603349 DOI: 10.1182/bloodadvances.2023009681 |
0.308 |
|
| 2023 |
Yadav U, Kumar SK, Baughn LB, Dispenzieri A, Greipp PT, Ketterling RP, Jevremovic D, Buadi FK, Dingli D, Lacy MQ, Fonseca R, Bergsagel PL, Ailawadhi S, Roy V, Parrondo RD, ... ... Rajkumar SV, et al. Impact of Cytogenetic Abnormalities on the Risk of Disease Progression in Solitary Bone Plasmacytomas. Blood. PMID 37494698 DOI: 10.1182/blood.2023021187 |
0.326 |
|
| 2023 |
Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, ... ... Rajkumar SV, et al. Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival. American Journal of Hematology. PMID 36588396 DOI: 10.1002/ajh.26806 |
0.334 |
|
| 2022 |
Rajkumar SV, Kumar S, Lonial S, Mateos MV. Smoldering multiple myeloma current treatment algorithms. Blood Cancer Journal. 12: 129. PMID 36064707 DOI: 10.1038/s41408-022-00719-0 |
0.324 |
|
| 2021 |
Al Saleh AS, Visram A, Parmar H, Muchtar E, Buadi FK, Dispenzieri A, Warsame R, Lacy MQ, Dingli D, Leung N, Go RS, Gonsalves WI, Kourelis TV, Hayman SR, Kapoor P, ... ... Rajkumar SV, et al. Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. Leukemia & Lymphoma. 1-8. PMID 34263694 DOI: 10.1080/10428194.2021.1950708 |
0.325 |
|
| 2021 |
Evans LA, Go R, Warsame R, Nandakumar B, Buadi FK, Dispenzieri A, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, ... ... Rajkumar SV, et al. The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. Clinical Lymphoma, Myeloma & Leukemia. PMID 33785296 DOI: 10.1016/j.clml.2021.02.001 |
0.314 |
|
| 2021 |
Facon T, Venner CP, Bahlis NJ, Offner F, White D, Karlin L, Benboubker L, Rigaudeau S, Rodon P, Voog E, Yoon SS, Suzuki K, Shibayama H, Zhang X, Twumasi-Ankrah P, ... ... Rajkumar SV, et al. Oral ixazomib, lenalidomide, and dexamethasone for newly diagnosed transplant-ineligible multiple myeloma patients. Blood. PMID 33763699 DOI: 10.1182/blood.2020008787 |
0.308 |
|
| 2021 |
Visram A, Vaxman I, S Al Saleh A, Parmar H, Dispenzieri A, Kapoor P, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Warsame R, Kourelis T, Siddiqui M, Gonsalves W, ... ... Rajkumar SV, et al. Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. Leukemia. PMID 33623138 DOI: 10.1038/s41375-021-01180-x |
0.306 |
|
| 2021 |
Usmani SZ, Hoering A, Ailawadhi S, Sexton R, Lipe B, Hita SF, Valent J, Rosenzweig M, Zonder JA, Dhodapkar M, Callander N, Zimmerman T, Voorhees PM, Durie B, Rajkumar SV, et al. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. The Lancet. Haematology. 8: e45-e54. PMID 33357482 DOI: 10.1016/S2352-3026(20)30354-9 |
0.317 |
|
| 2020 |
Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder JA, Faber E, ... ... Rajkumar SV, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. The Lancet. Oncology. PMID 32866432 DOI: 10.1016/S1470-2045(20)30452-6 |
0.394 |
|
| 2020 |
Paquin A, Visram A, Kumar SK, Gertz MA, Cantwell H, Buadi FK, Lacy MQ, Dispenzieri A, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman SR, Lust JA, Russell SJ, ... ... Rajkumar SV, et al. Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma. Blood Cancer Journal. 10: 87. PMID 32859899 DOI: 10.1038/S41408-020-00353-8 |
0.467 |
|
| 2020 |
Abdallah N, Rajkumar SV, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, et al. Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer Journal. 10: 82. PMID 32782240 DOI: 10.1038/S41408-020-00348-5 |
0.365 |
|
| 2020 |
Abdallah N, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, ... ... Rajkumar SV, et al. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Advances. 4: 3509-3519. PMID 32750129 DOI: 10.1182/Bloodadvances.2020002218 |
0.344 |
|
| 2020 |
Muchtar E, Gertz MA, Kourelis TV, Sidana S, Go RS, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, ... ... Rajkumar SV, et al. Correction: Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia. PMID 32728185 DOI: 10.1038/S41375-020-0993-8 |
0.304 |
|
| 2020 |
Muchtar E, Gertz MA, Lacy MQ, Leung N, Buadi FK, Dingli D, Hayman SR, Go RS, Kapoor P, Gonsalves W, Kourelis TV, Warsame R, Hwa YL, Fonder A, Hobbs M, ... ... Rajkumar SV, et al. Refining amyloid complete hematological response: quantitative serum free light chains superior to ratio. American Journal of Hematology. PMID 32681737 DOI: 10.1002/Ajh.25940 |
0.344 |
|
| 2020 |
Kaiser M, Beksaç M, Gulbrandsen N, Schjesvold F, Hájek R, Moreau P, de Arriba de la Fuente F, Mateos MV, West S, Spencer A, Rajkumar SV, Suryanarayan K, Czorniak M, Li C, Teng Z, et al. Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. Annals of Hematology. PMID 32613281 DOI: 10.1007/S00277-020-04149-5 |
0.394 |
|
| 2020 |
Abdallah N, Sidana S, Dispenzieri A, Lacy M, Buadi F, Hayman S, Kapoor P, Leung N, Dingli D, Hwa YL, Lust J, Russell S, Gonsalves W, Go R, Hogan W, ... ... Rajkumar SV, et al. Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. Bone Marrow Transplantation. PMID 32518290 DOI: 10.1038/S41409-020-0964-8 |
0.432 |
|
| 2020 |
Mellors PW, Binder M, Ketterling RP, Greipp PT, Baughn LB, Peterson JF, Jevremovic D, Pearce KE, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, ... ... Rajkumar SV, et al. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Advances. 4: 2236-2244. PMID 32442300 DOI: 10.1182/Bloodadvances.2019001275 |
0.359 |
|
| 2020 |
Durie BGM, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, Dispenzieri A, Kahanic SP, Thakuri MC, Reu FJ, Reynolds CM, Orlowski RZ, Barlogie B. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer Journal. 10: 53. PMID 32393732 DOI: 10.1038/S41408-020-0311-8 |
0.425 |
|
| 2020 |
Al Saleh AS, Parmar HV, Visram A, Muchtar E, Buadi FK, Go RS, Dispenzieri A, Kapoor P, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kourelis TV, Gertz MA, ... ... Rajkumar SV, et al. Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. Clinical Lymphoma, Myeloma & Leukemia. PMID 32360276 DOI: 10.1016/J.Clml.2020.03.012 |
0.335 |
|
| 2020 |
Goldschmidt H, Dimopoulos MA, Rajkumar SV, Weisel KC, Moreau P, Chng WJ, Mikala G, Cavo M, Ramasamy K, Suryanarayan K, Teng Z, Labotka R, Mateos MV. Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. Leukemia. PMID 32327729 DOI: 10.1038/S41375-020-0819-8 |
0.415 |
|
| 2020 |
Sidana S, Milani P, Binder M, Basset M, Tandon N, Foli A, Dispenzieri A, Gertz MA, Hayman SR, Buadi FK, Lacy MQ, Kapoor P, Leung N, Rajkumar SV, Merlini G, et al. A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. Blood Cancer Journal. 10: 41. PMID 32286270 DOI: 10.1038/S41408-020-0306-5 |
0.361 |
|
| 2020 |
Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management American Journal of Hematology. 95: 548-567. PMID 32212178 DOI: 10.1002/Ajh.25791 |
0.441 |
|
| 2020 |
Di Bacco A, Bahlis NJ, Munshi NC, Avet-Loiseau H, Masszi T, Viterbo L, Pour L, Ganly P, Cavo M, Langer C, Kumar SK, Rajkumar SV, Keats JJ, Berg D, Lin J, et al. c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. European Journal of Haematology. PMID 32145111 DOI: 10.1111/Ejh.13405 |
0.387 |
|
| 2020 |
Evans LA, Jevremovic D, Nandakumar B, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, ... ... Rajkumar SV, et al. Utilizing Multiparametric Flow Cytometry in the Diagnosis of Patients with Primary Plasma Cell Leukemia. American Journal of Hematology. PMID 32129510 DOI: 10.1002/Ajh.25773 |
0.396 |
|
| 2020 |
Dispenzieri A, Arendt B, Dasari S, Kohlhagen M, Kourelis T, Kumar SK, Leung N, Muchtar E, Buadi FK, Warsame R, Kyle RA, Lacy MQ, Dingli D, Kapoor P, Gonsalves WI, ... ... Rajkumar SV, et al. Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. Blood Cancer Journal. 10: 20. PMID 32098948 DOI: 10.1038/S41408-020-0291-8 |
0.332 |
|
| 2020 |
Sidana S, Muchtar E, Sidiqi MH, Jevremovic D, Dispenzieri A, Gonsalves W, Buadi F, Lacy MQ, Hayman SR, Kourelis T, Kapoor P, Go RS, Warsame R, Leung N, Rajkumar SV, et al. Impact of Minimal Residual Negativity using Next Generation Flow Cytometry on Outcomes in Light Chain Amyloidosis. American Journal of Hematology. PMID 32010993 DOI: 10.1002/Ajh.25746 |
0.443 |
|
| 2020 |
Abdallah N, Kapoor P, Murray DL, Buadi FK, Dingli D, Dispenzieri A, Gertz MA, Go RS, Gonsalves WI, Hayman SR, Kourelis TV, Lacy MQ, Leung N, Lust JA, Muchtar E, ... ... Rajkumar SV, et al. Utility of serum free light chain ratio in response definition in patients with multiple myeloma. Blood Advances. 4: 322-326. PMID 31978213 DOI: 10.1182/Bloodadvances.2019001099 |
0.38 |
|
| 2020 |
Chakraborty R, Bin Riaz I, Malik SU, Marneni N, Mejia Garcia A, Anwer F, Khorana AA, Rajkumar SV, Kumar S, Murad MH, Wang Z, Khan SU, Majhail NS. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis. Cancer. PMID 31913498 DOI: 10.1002/Cncr.32682 |
0.345 |
|
| 2020 |
Kapoor P, Rajkumar SV. Smoldering Multiple Myeloma: To Treat or Not to Treat. Cancer Journal (Sudbury, Mass.). 25: 65-71. PMID 30694862 DOI: 10.1097/Ppo.0000000000000350 |
0.404 |
|
| 2020 |
Kumar S, Jacobus SJ, Cohen AD, Weiss M, Callander NS, Singh AA, Parker TL, Menter AR, Yang X, Parsons BM, Kumar P, Kapoor P, Rosenberg AS, Zonder JA, Faber EA, ... ... Rajkumar SV, et al. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.18_Suppl.Lba3 |
0.321 |
|
| 2020 |
Abdallah N, Buadi F, Greipp PT, Gertz MA, Kapoor P, Dispenzieri A, Baughn L, Lacy M, Hayman SR, Dingli D, Go RS, Hobbs MA, Lin Y, Kourelis T, Siddiqui MA, ... ... Rajkumar SV, et al. Cytogenetic abnormalities in MM: Association with disease characteristics and treatment response. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E20520 |
0.369 |
|
| 2020 |
Nandakumar BN, Kumar S, Dispenzieri A, Buadi F, Dingli D, Lacy M, Kapoor P, Lin Y, Kourelis T, Muchtar E, Lust JA, Go RS, Warsame RM, Hayman SR, Leung N, ... ... Rajkumar SV, et al. Outcomes of patients with primary plasma cell leukemia (pPCL) in the era of novel agent therapy. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E20510 |
0.399 |
|
| 2020 |
Usmani SZ, Ailawadhi S, Sexton R, Hoering A, Lipe B, Hita S, Durie BG, Zonder JA, Dhodapkar MV, Callander NS, Rajkumar SV, Voorhees PM, Richardson PG, Orlowski RZ. Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211). Journal of Clinical Oncology. 38: 8507-8507. DOI: 10.1200/Jco.2020.38.15_Suppl.8507 |
0.461 |
|
| 2020 |
Cook J, Hathcock M, Gertz M, Gonsalves WI, Dingli D, Lacy M, Kapoor P, Dispenzieri A, Kourelis T, Warsame R, Fonder A, Hayman SR, Hobbs M, Hwa L, Kyle R, ... ... Rajkumar SV, et al. Utilization of Cryopreserved Stem Cell Re-Infusion without Conditioning Chemotherapy in Primary and Secondary Autologous Graft Failure Following an Autologous Stem Cell Transplant in Multiple Myeloma Biology of Blood and Marrow Transplantation. 26: S228. DOI: 10.1016/J.Bbmt.2019.12.468 |
0.355 |
|
| 2019 |
Gonsalves WI, Jevremovic D, Nandakumar B, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, ... ... Rajkumar SV, et al. Enhancing the R-ISS Classification of Newly Diagnosed Multiple Myeloma by Quantifying Circulating Clonal Plasma Cells. American Journal of Hematology. PMID 31867775 DOI: 10.1002/Ajh.25709 |
0.342 |
|
| 2019 |
Murray D, Kumar SK, Kyle RA, Dispenzieri A, Dasari S, Larson DR, Vachon C, Cerhan JR, Rajkumar SV. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. Blood Cancer Journal. 9: 102. PMID 31836698 DOI: 10.1038/S41408-019-0263-Z |
0.311 |
|
| 2019 |
Zanwar S, Abeykoon JP, Durot E, King R, Perez Burbano GE, Kumar S, Gertz MA, Quinquenel A, Delmer A, Gonsalves W, Cornillet-Lefebvre P, He R, Warsame R, Buadi FK, Novak AJ, ... ... Rajkumar SV, et al. Impact of MYD88 Mutation Status on Histological Transformation of Waldenström Macroglobulinemia. American Journal of Hematology. PMID 31814157 DOI: 10.1002/Ajh.25697 |
0.308 |
|
| 2019 |
Sidana S, Larson DP, Greipp PT, He R, McPhail ED, Dispenzieri A, Murray DL, Dasari S, Ansell SM, Muchtar E, Gonsalves WI, Kourelis TV, Ramirez-Alvarado M, Kapoor P, Rajkumar SV, et al. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia. PMID 31780812 DOI: 10.1038/S41375-019-0667-6 |
0.37 |
|
| 2019 |
Muchtar E, Gertz MA, Kourelis TV, Sidana S, Go RS, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Lisa Hwa Y, Gonsalves W, ... ... Rajkumar SV, et al. Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia. PMID 31758090 DOI: 10.1038/S41375-019-0655-X |
0.437 |
|
| 2019 |
Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet (London, England). PMID 31735560 DOI: 10.1016/S0140-6736(19)32556-5 |
0.388 |
|
| 2019 |
Nandakumar B, Kumar SK, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, ... ... Rajkumar SV, et al. Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. Clinical Lymphoma, Myeloma & Leukemia. PMID 31685378 DOI: 10.1016/J.Clml.2019.09.624 |
0.371 |
|
| 2019 |
Al Saleh AS, Sidiqi MH, Dispenzieri A, Kapoor P, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kourelis TV, Gertz MA, Go RS, Kyle RA, ... Rajkumar SV, et al. Hematopoietic Score Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. American Journal of Hematology. PMID 31612526 DOI: 10.1002/Ajh.25657 |
0.362 |
|
| 2019 |
Muchtar E, Dispenzieri A, Jevremovic D, Dingli D, Buadi FK, Lacy MQ, Gonsalves W, Warsame R, Kourelis TV, Hayman SR, Kapoor P, Leung N, Russell S, Lust JA, Lin Y, ... ... Rajkumar SV, et al. Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 1-4. PMID 31544536 DOI: 10.1080/13506129.2019.1666709 |
0.41 |
|
| 2019 |
Misund K, Keane N, Stein CK, Asmann YW, Day G, Welsh S, Van Wier SA, Riggs DL, Ahmann G, Chesi M, Viswanatha DS, Kumar SK, Dispenzieri A, Gonzalez-Calle V, Kyle RA, ... ... Rajkumar SV, et al. MYC dysregulation in the progression of multiple myeloma. Leukemia. PMID 31439946 DOI: 10.1038/S41375-019-0543-4 |
0.309 |
|
| 2019 |
Muchtar E, Gertz MA, Lacy MQ, Go RS, Buadi FK, Dingli D, Grogan M, AbouEzzeddine OF, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, ... ... Rajkumar SV, et al. Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. British Journal of Haematology. PMID 31298751 DOI: 10.1111/Bjh.16096 |
0.415 |
|
| 2019 |
Hsieh RW, Go RS, Abeykoon JP, Kapoor P, Kumar SK, Gertz MA, Buadi FK, Leung N, Gonsalves WI, Kourelis TV, Warsame RM, Dispenzieri A, Lacy MQ, Kyle RA, Rajkumar SV, et al. Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. Cancer. PMID 31251390 DOI: 10.1002/Cncr.32357 |
0.337 |
|
| 2019 |
Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, et al. Impact of acquired del(17p) in multiple myeloma. Blood Advances. 3: 1930-1938. PMID 31248884 DOI: 10.1182/Bloodadvances.2018028530 |
0.416 |
|
| 2019 |
Rajkumar SV. Multiple myeloma: Every year a new standard? Hematological Oncology. 37: 62-65. PMID 31187526 DOI: 10.1002/Hon.2586 |
0.318 |
|
| 2019 |
Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Serra ER, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. The Lancet. Oncology. 20: e302-e312. PMID 31162104 DOI: 10.1016/S1470-2045(19)30309-2 |
0.332 |
|
| 2019 |
Mellors PW, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust SR, ... ... Rajkumar SV, et al. Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. Leukemia & Lymphoma. 1-8. PMID 31096812 DOI: 10.1080/10428194.2019.1613536 |
0.415 |
|
| 2019 |
Aljama MA, Sidiqi MH, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, ... ... Rajkumar SV, et al. Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. Blood Advances. 3: 1226-1229. PMID 30975646 DOI: 10.1182/Bloodadvances.2019032458 |
0.347 |
|
| 2019 |
Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Dispenzieri A, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, et al. Natural history of multiple myeloma with de novo del(17p). Blood Cancer Journal. 9: 32. PMID 30846679 DOI: 10.1038/S41408-019-0191-Y |
0.397 |
|
| 2019 |
Ramakrishnan VG, Miller KC, Macon EP, Kimlinger TK, Haug J, Kumar S, Gonsalves WI, Rajkumar SV, Kumar SK. Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma. Haematologica. PMID 30846494 DOI: 10.3324/Haematol.2018.211110 |
0.31 |
|
| 2019 |
Sidiqi MH, McPhail ED, Theis JD, Dasari S, Vrana JA, Drosou ME, Leung N, Hayman S, Rajkumar SV, Warsame R, Ansell SM, Gertz MA, Grogan M, Dispenzieri A. Two types of amyloidosis presenting in a single patient: a case series. Blood Cancer Journal. 9: 30. PMID 30837451 DOI: 10.1038/S41408-019-0193-9 |
0.383 |
|
| 2019 |
Sidana S, Tandon N, Gertz MA, Dispenzieri A, Ramirez-Alvarado M, Murray DL, Kourelis TV, Buadi FK, Kapoor P, Gonsalves W, Warsame R, Lacy MQ, Kyle RA, Rajkumar SV, Kumar SK, et al. Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis. British Journal of Haematology. PMID 30836444 DOI: 10.1111/Bjh.15832 |
0.353 |
|
| 2019 |
Tandon N, Sidana S, Rajkumar SV, Gertz MA, Buadi FK, Lacy MQ, Kapoor P, Gonsalves WI, Dispenzieri A, Kourelis TV, Warsame R, Dingli D, Fonder AL, Hayman SR, Hobbs MA, et al. Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. Blood Advances. 3: 744-750. PMID 30824418 DOI: 10.1182/Bloodadvances.2018022806 |
0.446 |
|
| 2019 |
Kyriakou C, Molloy S, Vrionis F, Alberico R, Bastian L, Zonder JA, Giralt S, Raje N, Kyle RA, Roodman DGD, Dimopoulos MA, Rajkumar SV, Durie BBG, Terpos E. The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG). Blood Cancer Journal. 9: 27. PMID 30808868 DOI: 10.1038/S41408-019-0187-7 |
0.326 |
|
| 2019 |
Goyal G, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, et al. Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. Leukemia. PMID 30787429 DOI: 10.1038/S41375-019-0419-7 |
0.401 |
|
| 2019 |
Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, et al. Substratification of patients with newly diagnosed standard-risk multiple myeloma. British Journal of Haematology. PMID 30768679 DOI: 10.1111/Bjh.15800 |
0.407 |
|
| 2019 |
Hwa YL, Gertz MA, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Kapoor P, Zeldenrust SR, Leung N, Hayman SR, Gonsalves WI, Kourelis TV, Warsame R, Go RS, Muchtar E, ... ... Rajkumar SV, et al. Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. Leukemia. PMID 30737485 DOI: 10.1038/S41375-019-0400-5 |
0.375 |
|
| 2019 |
Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Rajkumar SV, Richardson PG. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia. PMID 30696949 DOI: 10.1038/S41375-019-0384-1 |
0.422 |
|
| 2019 |
Kumar SK, Buadi FK, Rajkumar SV. Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing Blood. 133: 652-659. PMID 30587528 DOI: 10.1182/Blood-2018-08-825349 |
0.397 |
|
| 2019 |
Thompson MA, Jacobus SJ, Kumar S, Janakiram M, Lonial S, Weiss M, Callander NS, Rajkumar SV. ECOG-ACRIN EAA172: Phase 1/2 study of daratumumab, bortezomib, dexamethasone (DVd) with or without venetoclax in relapsed/refractory multiple myeloma (RRMM) with assessment for t(11;14) status. Journal of Clinical Oncology. 37: TPS8052-TPS8052. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps8052 |
0.357 |
|
| 2019 |
Nandakumar B, Gonsalves WI, Buadi F, Dispenzieri A, Dingli D, Lacy M, Kapoor P, Lin Y, Kourelis T, Muchtar E, Go RS, Warsame RM, Hayman SR, Leung N, Hwa L, ... ... Rajkumar SV, et al. Clinical and cytogenetic features of nonsecretory multiple myeloma (NSMM) in the era of novel agent induction therapy: The Mayo Clinic experience. Journal of Clinical Oncology. 37: e19519-e19519. DOI: 10.1200/Jco.2019.37.15_Suppl.E19519 |
0.467 |
|
| 2019 |
Chakraborty R, Riaz IB, Malik S, Marneni N, Garcia AM, Anwer F, Khorana AA, Rajkumar SV, Kumar S, Murad MH, Wang Z, Khan SU, Majhail NS. Venous thromboembolism risk with contemporary lenalidomide-based regimes for multiple myeloma: A systematic review and meta-analysis. Journal of Clinical Oncology. 37: e19503-e19503. DOI: 10.1200/Jco.2019.37.15_Suppl.E19503 |
0.408 |
|
| 2019 |
Pang L, Kumar S, Lakshman A, Kyle RA, Rajkumar SV. Prognosis of young patients with monoclonal gammopathy of undetermined significance. Journal of Clinical Oncology. 37: 8049-8049. DOI: 10.1200/Jco.2019.37.15_Suppl.8049 |
0.346 |
|
| 2019 |
Nandakumar B, Binder M, Dispenzieri A, Kapoor P, Buadi F, Gertz MA, Lacy M, Dingli D, Hwa L, Leung N, Hayman SR, Gonsalves WI, Kourelis T, Muchtar E, Warsame RM, ... ... Rajkumar SV, et al. Continued improvement in survival in multiple myeloma (MM) including high-risk patients. Journal of Clinical Oncology. 37: 8039-8039. DOI: 10.1200/Jco.2019.37.15_Suppl.8039 |
0.426 |
|
| 2019 |
Tschautscher M, Jevremovic D, Buadi F, Lacy M, Gertz MA, Dispenzieri A, Kapoor P, Dingli D, Hayman SR, Lust JA, Russell SJ, Leung N, Go RS, Lin Y, Gonsalves WI, ... ... Rajkumar SV, et al. Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. Journal of Clinical Oncology. 37: 8034-8034. DOI: 10.1200/Jco.2019.37.15_Suppl.8034 |
0.397 |
|
| 2019 |
Gonsalves WI, Jevremovic D, Dispenzieri A, Buadi F, Dingli D, Lacy M, Kapoor P, Lin Y, Kourelis T, Muchtar E, Lust JA, Russell SJ, Go RS, Hayman SR, Leung N, ... ... Rajkumar SV, et al. Upstaging the R-ISS classification of newly diagnosed multiple myeloma (NDMM) patients (pts) by quantifying circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC). Journal of Clinical Oncology. 37: 8031-8031. DOI: 10.1200/Jco.2019.37.15_Suppl.8031 |
0.337 |
|
| 2019 |
Dispenzieri A, Soof CM, Rajkumar SV, Gertz MA, Kumar S, Bujarski S, Kyle RA, Berenson JR. Serum BCMA levels to predict outcomes for patients with MGUS and smoldering multiple myeloma (SMM). Journal of Clinical Oncology. 37: 8020-8020. DOI: 10.1200/Jco.2019.37.15_Suppl.8020 |
0.315 |
|
| 2019 |
Dispenzieri A, Lacy M, Mauermann M, LaPlant B, Go RS, Kapoor P, Leung N, Hwa YL, Fonder A, Buadi F, Hayman SR, Lust JA, Dingli D, Gonsalves WI, Kourelis T, ... ... Rajkumar SV, et al. Ixazomib, lenalidomide, and dexamethasone for patients with POEMS syndrome. Journal of Clinical Oncology. 37: 8019-8019. DOI: 10.1200/Jco.2019.37.15_Suppl.8019 |
0.388 |
|
| 2019 |
Durie BG, Goldschmidt H, Mateos M, Gonzalez V, Du J, Kim K, Merlini G, Mangiacavalli S, Min CK, Dimopoulos MA, Kastritis E, Ludwig H, Esteves G, Handa H, Escalante F, ... ... Rajkumar SV, et al. Outcomes of patients with t(11;14) multiple myeloma: An International Myeloma Working Group (IMWG) multicenter study. Journal of Clinical Oncology. 37: 8015-8015. DOI: 10.1200/Jco.2019.37.15_Suppl.8015 |
0.393 |
|
| 2019 |
Richardson PG, Attal M, Rajkumar SV, Miguel JS, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, et al. A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). Journal of Clinical Oncology. 37: 8004-8004. DOI: 10.1200/Jco.2019.37.15_Suppl.8004 |
0.343 |
|
| 2019 |
Lonial S, Jacobus SJ, Weiss M, Kumar S, Orlowski RZ, Kaufman JL, Yacoub A, Buadi F, O'Brien TE, Matous J, Anderson DM, Emmons R, Dhodapkar MV, Wagner LI, Rajkumar SV. E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma. Journal of Clinical Oncology. 37: 8001-8001. DOI: 10.1200/Jco.2019.37.15_Suppl.8001 |
0.371 |
|
| 2019 |
San Miguel J, Mateos M, Gonzalez V, Dimopoulos MA, Kastritis E, Hajek R, Fernández de Larrea Rodríguez C, Morgan GJ, Merlini G, Mangiacavalli S, Goldschmidt H, Cavo M, Kyriakou C, Qi M, Ukropec J, ... ... Rajkumar SV, et al. Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria. Journal of Clinical Oncology. 37: 8000-8000. DOI: 10.1200/Jco.2019.37.15_Suppl.8000 |
0.374 |
|
| 2019 |
Abeykoon JP, Zanwar S, Ansell SM, Kumar S, Thompson CA, Habermann TM, Witzig TE, Buadi F, Go RS, Gonsalves WI, Leung N, Dispenzieri A, Kourelis T, Lacy M, Warsame RM, ... ... Rajkumar SV, et al. Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM). Journal of Clinical Oncology. 37: 7509-7509. DOI: 10.1200/Jco.2019.37.15_Suppl.7509 |
0.36 |
|
| 2019 |
Sidana S, Dueck AC, Burtis M, Griffin JM, Thanarajasingam G, Warsame RM, Thompson CA, Cheville AL, Gertz MA, Yost KJ, Dispenzieri A, Villasboas Bisneto J, Paludo J, Ansell SM, Rajkumar SV, et al. Quality of life (QOL) in patients undergoing CAR-T therapy versus stem cell transplant (SCT). Journal of Clinical Oncology. 37: 6594-6594. DOI: 10.1200/Jco.2019.37.15_Suppl.6594 |
0.337 |
|
| 2019 |
Buadi FK, Lacy MQ, Dispenzieri A, Perez G, Gertz MA, Kapoor P, Hayman SR, Dingli D, Go RS, Fonder A, Hwa YL, Hobbs MA, Gonsalves WI, Helgeson DK, Kourelis T, ... ... Rajkumar SV, et al. Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma Blood. 134: 1905-1905. DOI: 10.1182/Blood-2019-132035 |
0.44 |
|
| 2019 |
Abdallah N, Rajkumar SV, Jevremovic D, Kapoor P, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Dingli D, Muchtar E, Gonsalves WI, Kourelis T, Warsame RM, Siddiqui MA, et al. Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition Blood. 134: 3080-3080. DOI: 10.1182/Blood-2019-131835 |
0.427 |
|
| 2019 |
Malave GC, Kapoor P, Dispenzieri A, Gertz MA, Lacy MQ, Hayman SR, Dingli D, Buadi FK, Muchtar E, Gonsalves WI, Leung N, Go RS, Siddiqui M, Kourelis T, Warsame RM, ... ... Rajkumar SV, et al. Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma Blood. 134: 5833-5833. DOI: 10.1182/Blood-2019-131776 |
0.381 |
|
| 2019 |
Buadi FK, Lacy MQ, Laplant B, Wolfe E, Gertz MA, Ailawadhi S, Hayman SR, Go RS, Helgeson DK, Roy V, Reeder CB, Fonder A, Hwa YL, Hobbs MA, Bergsagel PL, ... ... Rajkumar SV, et al. Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma Blood. 134: 1904-1904. DOI: 10.1182/Blood-2019-131478 |
0.381 |
|
| 2019 |
Kapoor P, Gertz MA, Laplant B, Malave GC, Wolfe E, Muchtar E, Siddiqui MA, Gonsalves WI, Emanuel AR, Kourelis T, Warsame R, Dingli D, Buadi FK, Hayman SR, Leung N, ... ... Rajkumar SV, et al. Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Blood. 134: 864-864. DOI: 10.1182/Blood-2019-131476 |
0.443 |
|
| 2019 |
Zanwar S, Abeykoon JP, King RL, Fang H, Ansell SM, Gertz MA, Kyle RA, Habermann TM, Dingli D, Inwards DJ, Buadi FK, Go RS, Nowakowski G, Dispenzieri A, Lacy MQ, ... ... Rajkumar SV, et al. Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity? Blood. 134: 1532-1532. DOI: 10.1182/Blood-2019-131442 |
0.301 |
|
| 2019 |
Al Saleh AS, Sidiqi MH, Muchtar E, Dispenzieri A, Buadi FK, Warsame RM, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kourelis T, Kapoor P, Go RS, Kyle RA, Rajkumar SV, et al. Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis Blood. 134: 5532-5532. DOI: 10.1182/Blood-2019-131171 |
0.395 |
|
| 2019 |
Abeykoon JP, Murray DL, Murray I, Jevremovic D, Dispenzieri A, Arendt BK, Dasari S, Gertz MA, Gonsalves WI, Kourelis T, Muchtar E, Dingli D, Warsame RM, Go RS, Lacy MQ, ... ... Rajkumar SV, et al. Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma Blood. 134: 4386-4386. DOI: 10.1182/Blood-2019-130771 |
0.425 |
|
| 2019 |
Kumar SK, Greipp P, Gertz MA, Dispenzieri A, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Kapoor P, Go RS, Hwa YL, Fonder A, Hobbs MA, Lin Y, ... ... Rajkumar S, et al. A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH Blood. 134: 1800-1800. DOI: 10.1182/Blood-2019-130639 |
0.374 |
|
| 2019 |
Kloeber JA, Kimlinger TK, Haug JL, Henderson KJ, Rajkumar SV, Kumar SK. Immunological Consequences of Lenalidomide with and without Dexamethasone in Newly Diagnosed Multiple Myeloma Blood. 134: 3070-3070. DOI: 10.1182/Blood-2019-128335 |
0.336 |
|
| 2019 |
Evans LA, Go RS, Nandakumar B, Buadi FK, Dispenzieri A, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs MA, Hwa YL, Muchtar E, Warsame RM, ... ... Rajkumar SV, et al. The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma Blood. 134: 2197-2197. DOI: 10.1182/Blood-2019-128256 |
0.411 |
|
| 2019 |
Dispenzieri A, Mauermann M, Laplant B, Lacy MQ, Go RS, Kapoor P, Hwa YL, Fonder A, Hobbs MA, Buadi FK, Hayman SR, Leung N, Lust JA, Dingli D, Gonsalves WI, ... ... Rajkumar S, et al. A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome Blood. 134: 1846-1846. DOI: 10.1182/Blood-2019-127366 |
0.365 |
|
| 2019 |
Evans LA, Jevremovic D, Nandakumar B, Buadi FK, Dispenzieri A, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Go RS, Leung N, Fonder A, Hobbs MA, Hwa YL, Muchtar E, ... ... Rajkumar SV, et al. Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis Blood. 134: 4334-4334. DOI: 10.1182/Blood-2019-126777 |
0.393 |
|
| 2019 |
Clay-Gilmour AI, Hildebrandt M, Asmann Y, Brown EE, Hofmann JN, Spinelli J, Giles G, Bhatti P, Cozen W, Robinson DP, O'Brien DR, Rajkumar SV, Tian S, Berndt SI, Chanock SJ, et al. Association between a Polygenic Risk Score for Multiple Myeloma Risk and Overall Survival Blood. 134: 4366-4366. DOI: 10.1182/Blood-2019-126088 |
0.367 |
|
| 2019 |
Nandakumar B, Kumar SK, Buadi FK, Dispenzieri A, Dingli D, Lacy MQ, Kapoor P, Lin Y, Kourelis T, Muchtar E, Lust JA, Russell SJ, Go RS, Warsame RM, Hayman SR, ... ... Rajkumar SV, et al. Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy Blood. 134: 5490-5490. DOI: 10.1182/Blood-2019-126057 |
0.458 |
|
| 2019 |
Sidiqi MH, Al Saleh ASS, Vaxman I, Dispenzieri A, Buadi FK, Muchtar E, Warsame RM, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis T, Rajkumar SV, Kumar SK, et al. Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant Blood. 134: 3171-3171. DOI: 10.1182/Blood-2019-125453 |
0.42 |
|
| 2019 |
Binder M, Nandakumar B, Gertz MA, Dispenzieri A, Lacy MQ, Maurer MJ, Hayman SR, Buadi FK, Dingli D, Kapoor P, Go RS, Hwa YL, Fonder A, Hobbs MA, Lin Y, ... ... Rajkumar SV, et al. Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States Blood. 134: 72-72. DOI: 10.1182/Blood-2019-124936 |
0.377 |
|
| 2019 |
Mellors P, Binder M, Ketterling RP, Griepp P, Baughn LB, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Haymann S, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs MA, ... ... Rajkumar SV, et al. Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma Blood. 134: 4396-4396. DOI: 10.1182/Blood-2019-122291 |
0.399 |
|
| 2019 |
Sidana S, Thanarajasingam G, Griffin J, Thompson CA, Burtis M, Warsame R, Paludo J, Cheville A, Gertz MA, Dispenzieri A, Villasboas J, Ansell SM, Rajkumar SV, Yost KJ, Bennani NN, et al. Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life Blood. 134: 794-794. DOI: 10.1182/Blood-2019-121715 |
0.315 |
|
| 2019 |
Clay-Gilmour AI, Hildebrandt MA, Camp NJ, Ziv E, Brown EE, Hofmann JN, Spinelli JJ, Giles GG, Bhatti P, Cozen W, Wu X, Robinson DP, Norman AD, Sinnwell JP, Kumar SK, ... Rajkumar SV, et al. Abstract 2686: Associations between a polygenic risk score and risk of multiple myeloma and its precursor Cancer Research. 79: 2686-2686. DOI: 10.1158/1538-7445.Am2019-2686 |
0.319 |
|
| 2019 |
Sidiqi MH, Aljama M, Kumar S, Jevremovic D, Buadi F, Warsame R, Lacy M, Dingli D, Gonsalves W, Kapoor P, Kourelis T, Leung N, Muchtar E, Lust J, Kyle R, ... ... Rajkumar SV, et al. The role of bone marrow biopsy in patients with plasma cell disorders; should all patients with a monoclonal protein be biopsied? Clinical Lymphoma, Myeloma & Leukemia. 19. DOI: 10.1016/J.Clml.2019.09.547 |
0.346 |
|
| 2019 |
Dispenzieri A, Soof C, Rajkumar SV, Gertz MA, Kumar S, Bujarski S, Kyle R, Berenson J. Serum BCMA Levels Predict Outcomes for Patients with MGUS and Smoldering Multiple Myeloma (SMM) Clinical Lymphoma, Myeloma & Leukemia. 19. DOI: 10.1016/J.Clml.2019.09.513 |
0.313 |
|
| 2019 |
Dispenzieri A, Lacy M, Mauermann M, LaPlant B, Go R, Kapoor P, Hwa YL, Fonder A, Hobbs M, Buadi F, Hayman S, Leung N, Lust J, Dingli D, Gonsalves W, ... ... Rajkumar SV, et al. Pilot study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with POEMS Syndrome Clinical Lymphoma, Myeloma & Leukemia. 19. DOI: 10.1016/J.Clml.2019.09.512 |
0.306 |
|
| 2019 |
Saleh ASA, Sidiqi MH, Dispenzieri A, Muchtar E, Buadi F, Warsame R, Lacy M, Dingli D, Leung N, Gonsalves W, Kapoor P, Kourelis T, Gertz MA, Go R, Kyle R, ... Rajkumar SV, et al. A Hematopoietic Score Predicts Survival in Newly Diagnosed Multiple Myeloma Patients. Clinical Lymphoma, Myeloma & Leukemia. 19. DOI: 10.1016/J.Clml.2019.09.137 |
0.378 |
|
| 2018 |
Sidana S, Jevremovic D, Ketterling RP, Tandon N, Dispenzieri A, Gertz MA, Greipp PT, Baughn LB, Buadi FK, Lacy MQ, Morice W, Hanson C, Timm M, Dingli D, Hayman SR, ... ... Rajkumar SV, et al. Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. American Journal of Hematology. PMID 30592078 DOI: 10.1002/Ajh.25391 |
0.399 |
|
| 2018 |
Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, ... ... Rajkumar SV, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet (London, England). PMID 30545780 DOI: 10.1016/S0140-6736(18)33003-4 |
0.373 |
|
| 2018 |
Paquin AR, Kumar SK, Buadi FK, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, ... ... Rajkumar SV, et al. Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. Blood Cancer Journal. 8: 125. PMID 30538223 DOI: 10.1038/S41408-018-0163-7 |
0.451 |
|
| 2018 |
Binder M, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa L, Fonder A, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, et al. Peripheral Blood Biomarkers of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. American Journal of Hematology. PMID 30516847 DOI: 10.1002/Ajh.25365 |
0.341 |
|
| 2018 |
Usmani SZ, Hoering A, Cavo M, Miguel JS, Goldschimdt H, Hajek R, Turesson I, Lahuerta JJ, Attal M, Barlogie B, Lee JH, Kumar S, Lenhoff S, Morgan G, Rajkumar SV, et al. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project. Blood Cancer Journal. 8: 123. PMID 30470751 DOI: 10.1038/S41408-018-0155-7 |
0.351 |
|
| 2018 |
Aljama MA, Sidiqi MH, Lakshman A, Dispenzieri A, Jevremovic D, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame R, ... ... Rajkumar SV, et al. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Advances. 2: 3149-3154. PMID 30463914 DOI: 10.1182/bloodadvances.2018024794 |
0.313 |
|
| 2018 |
Ravi P, Kumar SK, Roeker L, Gonsalves W, Buadi F, Lacy MQ, Go RS, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, ... ... Rajkumar SV, et al. Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer Journal. 8: 116. PMID 30442928 DOI: 10.1038/S41408-018-0140-1 |
0.414 |
|
| 2018 |
Sidiqi MH, Aljama MA, Bin Riaz I, Dispenzieri A, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Rajkumar SV, et al. Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. Blood Cancer Journal. 8: 106. PMID 30409963 DOI: 10.1038/S41408-018-0147-7 |
0.44 |
|
| 2018 |
Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management American Journal of Hematology. 93: 1091-1110. PMID 30400719 DOI: 10.1002/Ajh.25117 |
0.452 |
|
| 2018 |
Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, ... ... Rajkumar SV, et al. Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. Leukemia. PMID 30323358 DOI: 10.1038/S41375-018-0271-1 |
0.435 |
|
| 2018 |
Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Dispenzieri A, Muchtar E, Sidana S, Tandon N, Rajkumar SV, Dingli D, Go R, Lacy MQ, Kourelis T, Witzig TE, Inwards D, et al. Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. Leukemia. PMID 30315235 DOI: 10.1038/S41375-018-0286-7 |
0.306 |
|
| 2018 |
Baughn LB, Pearce K, Larson D, Polley MY, Elhaik E, Baird M, Colby C, Benson J, Li Z, Asmann Y, Therneau T, Cerhan JR, Vachon CM, Stewart AK, Bergsagel PL, ... ... Rajkumar SV, et al. Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry. Blood Cancer Journal. 8: 96. PMID 30305608 DOI: 10.1038/S41408-018-0132-1 |
0.302 |
|
| 2018 |
Moulopoulos LA, Koutoulidis V, Hillengass J, Zamagni E, Aquerreta JD, Roche CL, Lentzsch S, Moreau P, Cavo M, Miguel JS, Dimopoulos MA, Rajkumar SV, Durie BGM, Terpos E, Delorme S. Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. Blood Cancer Journal. 8: 95. PMID 30287814 DOI: 10.1038/S41408-018-0124-1 |
0.356 |
|
| 2018 |
Clay-Gilmour AI, Kumar S, Rajkumar SV, Rishi A, Kyle RA, Katzmann JA, Murray DL, Norman AD, Greenberg AJ, Larson DR, O'Byrne MM, Slager SL, Vachon CM. Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics. Leukemia. PMID 30201985 DOI: 10.1038/S41375-018-0246-2 |
0.642 |
|
| 2018 |
Aljama MA, Sidiqi MH, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, ... ... Rajkumar SV, et al. Utility and Prognostic Value of F-FDG Positron Emission Tomography-Computed Tomography Scans in Patients With Newly Diagnosed Multiple Myeloma. American Journal of Hematology. PMID 30194770 DOI: 10.1002/Ajh.25279 |
0.353 |
|
| 2018 |
Mikhael J, Manola J, Dueck AC, Hayman S, Oettel K, Kanate AS, Lonial S, Rajkumar SV. Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study. Blood Cancer Journal. 8: 86. PMID 30190454 DOI: 10.1038/S41408-018-0110-7 |
0.35 |
|
| 2018 |
Abeykoon JP, Zanwar S, Ansell SM, Winters J, Gertz MA, King RL, Murray D, Habermann T, Dingli D, Muchtar E, Go RS, Leung N, Inwards DJ, Buadi FK, Dispenzieri A, ... ... Rajkumar SV, et al. Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. American Journal of Hematology. PMID 30121949 DOI: 10.1002/Ajh.25254 |
0.414 |
|
| 2018 |
Kumar SK, Buadi FK, LaPlant B, Halvorson A, Leung N, Kapoor P, Dingli D, Gertz MA, Go RS, Bergsagel PL, Lin Y, Dispenzieri A, Hwa YL, Fonder A, Hobbs M, ... ... Rajkumar SV, et al. Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer Journal. 8: 70. PMID 30061664 DOI: 10.1038/S41408-018-0106-3 |
0.41 |
|
| 2018 |
Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, Dispenzieri A, Fonseca R, Hayman SR, Kapoor P, Kourelis TV, Lacy MQ, Larsen JT, Muchtar E, Reeder CB, ... ... Rajkumar SV, et al. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplantation. PMID 29988062 DOI: 10.1038/S41409-018-0264-8 |
0.378 |
|
| 2018 |
Ailawadhi S, Jacobus S, Sexton R, Stewart AK, Dispenzieri A, Hussein MA, Zonder JA, Crowley J, Hoering A, Barlogie B, Orlowski RZ, Rajkumar SV. Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer Journal. 8: 67. PMID 29980678 DOI: 10.1038/S41408-018-0102-7 |
0.394 |
|
| 2018 |
Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer Journal. 8: 59. PMID 29895887 DOI: 10.1038/S41408-018-0077-4 |
0.424 |
|
| 2018 |
Higgins L, Nasr SH, Said SM, Kapoor P, Dingli D, King RL, Rajkumar SV, Kyle RA, Kourelis T, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Ansell SM, Gonsalves WI, et al. Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders. Clinical Journal of the American Society of Nephrology : Cjasn. PMID 29848505 DOI: 10.2215/Cjn.13041117 |
0.302 |
|
| 2018 |
Lakshman A, Ravi P, Rajkumar SV, Kumar SK. Response to 'Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression'. Leukemia. PMID 29802327 DOI: 10.1038/S41375-018-0155-4 |
0.32 |
|
| 2018 |
Milani P, Dispenzieri A, Scott CG, Gertz MA, Perlini S, Mussinelli R, Lacy MQ, Buadi FK, Kumar S, Maurer MS, Merlini G, Hayman SR, Leung N, Dingli D, Klarich KW, ... ... Rajkumar SV, et al. Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. Circulation. Cardiovascular Imaging. 11: e006588. PMID 29752392 DOI: 10.1161/Circimaging.117.006588 |
0.323 |
|
| 2018 |
Kumar SK, Rajkumar SV. The multiple myelomas - current concepts in cytogenetic classification and therapy. Nature Reviews. Clinical Oncology. PMID 29686421 DOI: 10.1038/S41571-018-0018-Y |
0.38 |
|
| 2018 |
Mellors PW, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust SR, ... ... Rajkumar SV, et al. Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. American Journal of Hematology. PMID 29659048 DOI: 10.1002/Ajh.25113 |
0.435 |
|
| 2018 |
Kansagra A, Gonsalves WI, Gertz MA, Buadi FK, Dingli D, Dispenzieri A, Lacy MQ, Hayman SR, Kapoor P, Muchtar E, Kourelis TV, Warsame R, Leung N, Zeldenrust SR, Lust JA, ... Rajkumar SV, et al. Analysis of Clinical Factors and Outcomes Associated with Non-Utilization of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant Eligible Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29656139 DOI: 10.1016/J.Bbmt.2018.04.007 |
0.435 |
|
| 2018 |
Paludo J, Abeykoon JP, Shreders A, Ansell SM, Kumar S, Ailawadhi S, King RL, Koehler AB, Reeder CB, Buadi FK, Dispenzieri A, Lacy MQ, Dingli D, Witzig TE, Go RS, ... ... Rajkumar SV, et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. Annals of Hematology. PMID 29610969 DOI: 10.1007/S00277-018-3311-Z |
0.428 |
|
| 2018 |
Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Chakraborty R, Gonsalves W, Kourelis TV, ... ... Rajkumar SV, et al. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia. PMID 29581546 DOI: 10.1038/S41375-018-0060-X |
0.324 |
|
| 2018 |
Sidana S, Tandon N, Dispenzieri A, Gertz MA, Rajkumar SV, Kumar SK. The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response. Leukemia. PMID 29568089 DOI: 10.1038/S41375-018-0022-3 |
0.318 |
|
| 2018 |
Ravi P, Kumar SK, Cerhan JR, Maurer MJ, Dingli D, Ansell SM, Rajkumar SV. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer Journal. 8: 26. PMID 29531285 DOI: 10.1038/S41408-018-0065-8 |
0.407 |
|
| 2018 |
Sidana S, Tandon N, Dispenzieri A, Gertz MA, Dingli D, Jevremovic D, Morice WG, Kapoor P, Kourelis TV, Lacy MQ, Hayman SR, Buadi FK, Leung N, Go RS, Lin Y, ... ... Rajkumar SV, et al. Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. Leukemia. PMID 29483709 DOI: 10.1038/S41375-018-0063-7 |
0.424 |
|
| 2018 |
Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, Rajkumar SV. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. The New England Journal of Medicine. 378: 241-249. PMID 29342381 DOI: 10.1056/Nejmoa1709974 |
0.416 |
|
| 2018 |
Rajkumar S, Voorhees PM, Goldschmidt H, Baker RI, Bandekar R, Kuppens S, Neff T, Qi M, Dimopoulos MA. Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA. Journal of Clinical Oncology. 36: TPS8062-TPS8062. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps8062 |
0.331 |
|
| 2018 |
Lakshman A, Painuly U, Rajkumar SV, Dispenzieri A, Gertz MA, Buadi F, Lacy M, Dingli D, Hayman SR, Kourelis T, Warsame RM, Gonsalves WI, Kapoor P, Leung N, Go RS, et al. Natural history of delp53 multiple myeloma. Journal of Clinical Oncology. 36: e20017-e20017. DOI: 10.1200/Jco.2018.36.15_Suppl.E20017 |
0.358 |
|
| 2018 |
Abeykoon JP, Zanwar S, Kumar S, Dispenzieri A, Rajkumar SV, Lacy M, Dingli D, Leung N, Muchtar E, Gonsalves WI, Kourelis T, Buadi F, Kyle RA, Gertz MA, Kapoor P. Daratumumab-based therapies in patients with AL amyloidosis. Journal of Clinical Oncology. 36: 8053-8053. DOI: 10.1200/Jco.2018.36.15_Suppl.8053 |
0.386 |
|
| 2018 |
Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi F, Lacy M, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, ... ... Rajkumar SV, et al. Duration of complete response (DurCR) impacts overall survival (OS) in multiple myeloma (MM). Journal of Clinical Oncology. 36: 8045-8045. DOI: 10.1200/Jco.2018.36.15_Suppl.8045 |
0.374 |
|
| 2018 |
Tschautscher M, Rajkumar SV, Buadi F, Gertz MA, Lacy M, Dispenzieri A, Hayman SR, Hwa YL, Fonder AL, Hobbs MA, Zeldenrust SR, Lust JA, Leung N, Kapoor P, Kourelis T, et al. Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. Journal of Clinical Oncology. 36: 8030-8030. DOI: 10.1200/Jco.2018.36.15_Suppl.8030 |
0.405 |
|
| 2018 |
Zanwar S, Abeykoon JP, Ansell SM, Kumar S, Dispenzieri A, Witzig TE, Lacy M, Nowakowski GS, Buadi F, Dingli D, Leung N, Rajkumar SV, Go RS, Habermann TM, Lin Y, et al. Predictors of disease progression in smoldering Waldenström macroglobulinemia. Journal of Clinical Oncology. 36: 7571-7571. DOI: 10.1200/Jco.2018.36.15_Suppl.7571 |
0.331 |
|
| 2018 |
Grieb B, Abeykoon JP, Zanwar S, Rajkumar SV, Lacy MQ, Dispenzieri A, Gertz MA, Gonsalves WI, Go RS, Buadi FK, Dingli D, Haymann S, Warsame R, Kourelis T, Muchtar E, et al. Long-Term Survivorship with Active Multiple Myeloma Blood. 132: 1912-1912. DOI: 10.1182/Blood-2018-99-120152 |
0.393 |
|
| 2018 |
Sidiqi MH, Kumar SK, Dasari S, McPhail ED, Buadi FK, Warsame R, Lacy MQ, Dingli D, Gonsalves WI, Kapoor P, Kourelis T, Leung N, Muchtar E, Lust JA, Kyle RA, ... Rajkumar SV, et al. Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis Blood. 132: 5610-5610. DOI: 10.1182/Blood-2018-99-120058 |
0.362 |
|
| 2018 |
Abeykoon JP, Zanwar S, Ailawadhi S, Larsen J, Gertz MA, Gonsalves WI, Buadi FK, Kumar SK, Rajkumar SV, King RL, Inwards DJ, Lacy MQ, Habermann TM, Dispenzieri A, Witzig TE, et al. Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting Blood. 132: 1606-1606. DOI: 10.1182/Blood-2018-99-120044 |
0.416 |
|
| 2018 |
Dispenzieri A, Dasari S, Arendt BK, Kohlhagen MK, Kourelis T, Gertz MA, Kumar SK, Rajkumar SV, Buadi FK, Dingli D, Leung N, Kapoor P, Go RS, Kyle RA, Muchtar E, et al. Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL) Blood. 132: 4502-4502. DOI: 10.1182/Blood-2018-99-119969 |
0.344 |
|
| 2018 |
Zanwar S, Abeykoon JP, Ansell SM, Dispenzieri A, Gertz MA, Inwards DJ, Witzig TE, Lacy MQ, Habermann TM, Dingli D, Buadi FK, Go RS, Gonsalves WI, Muchtar E, Kyle RA, ... Rajkumar SV, et al. Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model Blood. 132: 4152-4152. DOI: 10.1182/Blood-2018-99-119849 |
0.327 |
|
| 2018 |
Lacy MQ, Peng K, Russell SJ, Dueck AC, Patnaik MM, Witzig TE, Ginos BF, Buadi FK, Dispenzieri A, Gertz MA, Go RS, Hayman SR, Lust JA, Dingli D, Rajkumar SV, et al. Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL) Blood. 132: 3268-3268. DOI: 10.1182/Blood-2018-99-119444 |
0.349 |
|
| 2018 |
Warsame R, Fruth B, Croghan K, Engebretson A, Kourelis T, Aug S, Ellingson S, Irlbeck C, Gertz MA, Buadi FK, Go RS, Gonsalves WI, Muchtar E, Kumar SK, Rajkumar SV, et al. Patient-Reported Outcome Driven Case Management System for Hematology – a Prospective Study Blood. 132: 719-719. DOI: 10.1182/Blood-2018-99-118744 |
0.307 |
|
| 2018 |
Binder M, Rajkumar SV, Lakshman A, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa L, Fonder A, Hobbs M, Hayman SR, Zeldenrust S, Lust JA, Russell SJ, Leung N, et al. Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma Blood. 132: 4497-4497. DOI: 10.1182/Blood-2018-99-118084 |
0.447 |
|
| 2018 |
Muchtar E, Gertz MA, Lacy MQ, Dingli D, Buadi FK, Grogan M, abou Ezzeddine OF, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa Y, Gonsalves WI, Warsame R, ... ... Rajkumar SV, et al. Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population Blood. 132: 3226-3226. DOI: 10.1182/Blood-2018-99-117802 |
0.397 |
|
| 2018 |
Aljama MA, Sidiqi MH, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder A, Hayman SR, Hobbs M, Gonsalves WI, Warsame R, Kourelis T, Hwa L, ... ... Rajkumar SV, et al. Comparison of Different Techniques to Identify Cardiac Involvement in Immunoglobulin Light Chain Amyloidosis Blood. 132: 3182-3182. DOI: 10.1182/Blood-2018-99-117627 |
0.357 |
|
| 2018 |
Baughn LB, Larson D, Polley M, Pearce KE, Elhaik E, Baird ML, Colby C, Benson J, Li Z, Asmann Y, Therneau T, Cerhan JR, Vachon CM, Stewart AK, Bergsagel PL, ... ... Rajkumar SV, et al. Genomic Abnormalities Among African Individuals with Monoclonal Gammopathies Using Calculated Ancestry Blood. 132: 4458-4458. DOI: 10.1182/Blood-2018-99-117382 |
0.312 |
|
| 2018 |
Durie BG, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, Dispenzieri A, Kahanic SP, Thakuri MC, Reu FJ, Reynolds CM, Orlowski RZ, Barlogie B. Longer Term Follow up of the  Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT) Blood. 132: 1992-1992. DOI: 10.1182/Blood-2018-99-117003 |
0.427 |
|
| 2018 |
Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp P, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Dispenzieri A, Fonder A, Hayman SR, Hobbs M, Gonsalves WI, et al. Impact of Acquired Del(17p) in Patients with Multiple Myeloma Blood. 132: 4449-4449. DOI: 10.1182/Blood-2018-99-115458 |
0.422 |
|
| 2018 |
Aljama MA, Sidiqi MH, Lakshman A, Dispenzieri A, Jevremovic D, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder A, Hayman SR, Hobbs M, Gonsalves WI, Warsame R, ... ... Rajkumar SV, et al. Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma Blood. 132: 3160-3160. DOI: 10.1182/Blood-2018-99-114882 |
0.393 |
|
| 2018 |
Binder M, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa L, Fonder A, Hobbs M, Hayman SR, Zeldenrust S, Lust JA, Russell SJ, Leung N, Kapoor P, et al. Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma Blood. 132: 3158-3158. DOI: 10.1182/Blood-2018-99-113970 |
0.401 |
|
| 2018 |
Muchtar E, Dispenzieri A, Leung N, Buadi FK, Dingli D, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves WI, Kourelis T, Warsame R, Russell SJ, Lust JA, ... ... Rajkumar SV, et al. Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy Blood. 132: 3227-3227. DOI: 10.1182/Blood-2018-99-113958 |
0.405 |
|
| 2018 |
Hwa YL, Gertz MA, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Kapoor P, Zeldenrust S, Leung N, Hayman SR, Gonsalves WI, Kourelis T, Warsame R, Go RS, Muchtar E, ... ... Rajkumar SV, et al. Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis Blood. 132: 5594-5594. DOI: 10.1182/Blood-2018-99-113805 |
0.374 |
|
| 2018 |
Mellors P, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa Y, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust S, ... ... Rajkumar SV, et al. Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma Blood. 132: 1902-1902. DOI: 10.1182/Blood-2018-99-112138 |
0.464 |
|
| 2018 |
Binder M, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa L, Fonder A, Hobbs M, Hayman SR, Zeldenrust S, Lust JA, Russell SJ, Leung N, Kapoor P, et al. Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma Blood. 132: 3159-3159. DOI: 10.1182/Blood-2018-99-111624 |
0.405 |
|
| 2018 |
Sidiqi MH, Aljama MA, Dispenzieri A, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis T, Hogan WJ, Rajkumar SV, Kumar SK, et al. Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience Blood. 132: 2147-2147. DOI: 10.1182/Blood-2018-99-111147 |
0.446 |
|
| 2018 |
Kumar SK, Kapoor P, Laplant B, Muchtar E, Buadi FK, Gonsalves WI, Dingli D, Go RS, Warsame R, Kourelis T, Lust JA, Lacy MQ, Dispenzieri A, Hayman SR, Hwa Y, ... ... Rajkumar SV, et al. Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma Blood. 132: 304-304. DOI: 10.1182/Blood-2018-99-111065 |
0.447 |
|
| 2018 |
Dimopoulos MA, Gay F, Schjesvold FH, Beksac M, Hajek R, Weisel K, Goldschmidt H, Maisnar V, Moreau P, Min C, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos M, ... ... Rajkumar SV, et al. Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial Blood. 132: 301-301. DOI: 10.1016/J.Bbmt.2018.12.087 |
0.35 |
|
| 2017 |
Sidana S, Tandon N, Gertz MA, Dispenzieri A, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, ... ... Rajkumar SV, et al. Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. Bone Marrow Transplantation. PMID 29269795 DOI: 10.1038/S41409-017-0020-5 |
0.334 |
|
| 2017 |
Go RS, Rajkumar SV. How I manage monoclonal gammopathy of undetermined significance. Blood. PMID 29183887 DOI: 10.1182/Blood-2017-09-807560 |
0.313 |
|
| 2017 |
Abeykoon JP, Paludo J, King RL, Ansell SM, Gertz MA, LaPlant BR, Halvorson AE, Gonsalves WI, Dingli D, Fang H, Rajkumar SV, Lacy MQ, He R, Kourelis T, Reeder CB, et al. Impact of MYD88 Mutation Status in Waldenström Macroglobulinemia. American Journal of Hematology. PMID 29080258 DOI: 10.1002/Ajh.24955 |
0.361 |
|
| 2017 |
Lakshman A, Singh PP, Rajkumar SV, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Hwa YL, Fonder AL, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, et al. Efficacy of VDT PACE-like Regimens in Treatment of Relapsed/Refractory Multiple Myeloma. American Journal of Hematology. PMID 29067723 DOI: 10.1002/Ajh.24954 |
0.465 |
|
| 2017 |
Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Langer C, Pluta A, Nagler A, Kumar S, Ben-Yehuda D, Rajkumar SV, et al. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. PMID 29054911 DOI: 10.1182/Blood-2017-06-791228 |
0.402 |
|
| 2017 |
Tandon N, Sidana S, Dispenzieri A, Gertz MA, Lacy MQ, Dingli D, Buadi FK, Fonder AL, Hayman SR, Hwa YL, Hobbs MA, Kapoor P, Gonsalves WI, Leung N, Go RS, ... ... Rajkumar SV, et al. Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). American Journal of Hematology. PMID 28960427 DOI: 10.1002/Ajh.24919 |
0.423 |
|
| 2017 |
Binder M, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, et al. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. Blood Cancer Journal. 7: e600. PMID 28862698 DOI: 10.1038/bcj.2017.83 |
0.305 |
|
| 2017 |
Hwa YL, Warsame R, Gertz MA, Buadi FK, Lacy MQ, Kumar SK, Dingli D, Zeldenrust SR, Leung N, Hayman SR, Kapoor P, Gonsalves WI, Kourelis TV, Russell S, Go RS, ... ... Rajkumar SV, et al. Delineation of the timing of second line therapy post- autologous stem cell transplant in patients with AL amyloidosis. Blood. PMID 28807981 DOI: 10.1182/Blood-2017-05-783415 |
0.415 |
|
| 2017 |
Lakshman A, Abeykoon JP, Kumar SK, Rajkumar SV, Dingli D, Buadi FK, Gonsalves WI, Leung N, Dispenzieri A, Kourelis TV, Go RS, Lacy MQ, Hobbs MA, Lin Y, Warsame R, et al. Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. American Journal of Hematology. PMID 28799231 DOI: 10.1002/Ajh.24883 |
0.441 |
|
| 2017 |
Paludo J, Abeykoon JP, Kumar S, Shreders A, Ailawadhi S, Gertz MA, Kourelis T, King RL, Reeder CB, Leung N, Kyle RA, Buadi FK, Habermann TM, Dingli D, Witzig TE, ... ... Rajkumar SV, et al. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. British Journal of Haematology. PMID 28786474 DOI: 10.1111/Bjh.14826 |
0.4 |
|
| 2017 |
Tandon N, Sidana S, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Kyle RA, Buadi FK, Dingli D, Hayman SR, Fonder AL, Hobbs MA, Gonsalves WI, Kapoor P, Hwa YL, et al. Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 1-6. PMID 28699793 DOI: 10.1080/13506129.2017.1351354 |
0.417 |
|
| 2017 |
Muchtar E, Dispenzieri A, Lacy MQ, Buadi FK, Kapoor P, Hayman SR, Gonsalves W, Warsame R, Kourelis TV, Chakraborty R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, ... ... Rajkumar SV, et al. Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. British Journal of Haematology. PMID 28699650 DOI: 10.1111/Bjh.14830 |
0.407 |
|
| 2017 |
Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, ... ... Rajkumar SV, et al. Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed, Lenalidomide Refractory Multiple Myeloma. Blood. PMID 28684537 DOI: 10.1182/Blood-2017-05-782961 |
0.424 |
|
| 2017 |
Kumar SK, Laubach JP, Giove TJ, Quick M, Neuwirth R, Yung G, Rajkumar SV, Richardson PG. Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. British Journal of Haematology. PMID 28591409 DOI: 10.1111/Bjh.14754 |
0.321 |
|
| 2017 |
Muchtar E, Dispenzieri A, Kumar SK, Buadi FK, Lacy MQ, Zeldenrust S, Hayman SR, Leung N, Kourelis TV, Gonsalves W, Chakraborty R, Russell S, Dingli D, Lust JA, Lin Y, ... ... Rajkumar SV, et al. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 24: 40-41. PMID 28434371 DOI: 10.1080/13506129.2016.1277696 |
0.31 |
|
| 2017 |
Abeykoon JP, Paludo J, Dispenzieri A, Gertz MA, Dingli D, Baudi FK, Gonsalves WI, Kyle RA, Lacy MQ, Hayman SR, Leung N, Kourelis T, Rajkumar SV, Kumar S, Kapoor P. Outcome of very young (≤40 years) patients with immunoglobulin light chain (AL) amyloidosis. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 24: 50-51. PMID 28434368 DOI: 10.1080/13506129.2017.1286584 |
0.319 |
|
| 2017 |
Sidana S, Rajkumar SV, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kapoor P, Gonsalves WI, Go RS, Hwa YL, Leung N, Fonder AL, Hobbs MA, et al. Clinical Presentation and Outcomes of Patients with Type 1 Monoclonal Cryoglobulinemia. American Journal of Hematology. PMID 28370486 DOI: 10.1002/Ajh.24745 |
0.381 |
|
| 2017 |
Tandon N, Sidana S, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Fonder AL, Hobbs MA, Hayman SR, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, ... ... Rajkumar SV, et al. Treatment Patterns and Outcome Following Initial Relapse or Refractory Disease in Patients with Systemic Light Chain Amyloidosis. American Journal of Hematology. PMID 28314084 DOI: 10.1002/Ajh.24723 |
0.407 |
|
| 2017 |
Warsame R, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Russell S, Kapoor P, Go RS, Kourelis T, Gonsalves W, ... ... Rajkumar SV, et al. Hematology Patient Reported Symptom Screen to Assess Quality of Life for AL Amyloidosis. American Journal of Hematology. PMID 28181278 DOI: 10.1002/Ajh.24676 |
0.385 |
|
| 2017 |
Muchtar E, Gertz MA, Kumar SK, Lacy MQ, Dingli D, Buadi FK, Grogan M, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, ... ... Rajkumar SV, et al. Improved outcomes for newly diagnosed AL amyloidosis over the years 2000-2014: cracking the glass ceiling of early death. Blood. PMID 28126928 DOI: 10.1182/Blood-2016-11-751628 |
0.446 |
|
| 2017 |
Kapoor P, Rajkumar SV. Multiple myeloma in 2016: Fresh perspectives on treatment and moments of clarity. Nature Reviews. Clinical Oncology. 14: 73-74. PMID 28071678 DOI: 10.1038/Nrclinonc.2016.221 |
0.37 |
|
| 2017 |
Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, ... ... Rajkumar SV, et al. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. Jama Oncology. PMID 28056114 DOI: 10.1001/Jamaoncol.2016.5763 |
0.302 |
|
| 2017 |
Muchtar E, Dispenzieri A, Lacy M, Buadi F, Kapoor P, Hayman SR, Gonsalves WI, Kourelis T, Chakraborty R, Russell SJ, Lust JA, Lin Y, Go RS, Zeldenrust SR, Rajkumar S, et al. Overuse of organ biopsies in immunoglobulin light chain (AL) amyloidosis: The consequence of failure of early recognition. Journal of Clinical Oncology. 35: e19532-e19532. DOI: 10.1200/Jco.2017.35.15_Suppl.E19532 |
0.323 |
|
| 2017 |
Kourelis T, Kapoor P, Dingli D, Stewart AK, Buadi F, Gertz MA, Lacy M, Kumar S, Gonsalves WI, Go RS, Lust JA, Hayman SR, Warsame RM, Rajkumar S, Zeldenrust SR, et al. The use of proteasome inhibitors among patients with POEMS syndrome. Journal of Clinical Oncology. 35: e19530-e19530. DOI: 10.1200/Jco.2017.35.15_Suppl.E19530 |
0.43 |
|
| 2017 |
Tandon N, Sidana S, Dispenzieri A, Gertz MA, Lacy M, Dingli D, Buadi F, Fonder AL, Hayman SR, Hwa YL, Hobbs MA, Kapoor P, Gonsalves WI, Leung N, Go RS, ... ... Rajkumar S, et al. Outcomes according to involved free light chain (FLC) levels in patients with normal FLC ratio after initial therapy in light chain amyloidosis (AL). Journal of Clinical Oncology. 35: 8049-8049. DOI: 10.1200/Jco.2017.35.15_Suppl.8049 |
0.374 |
|
| 2017 |
Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi F, Lacy M, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, ... ... Rajkumar SV, et al. Factors predicting organ response in light chain amyloidosis (AL). Journal of Clinical Oncology. 35: 8048-8048. DOI: 10.1200/Jco.2017.35.15_Suppl.8048 |
0.306 |
|
| 2017 |
Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi F, Lacy M, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, ... ... Rajkumar SV, et al. Risk stratification by detection of clonal circulating plasma cells (CPCs) by multi-parametric flow cytometry (MFC) in light chain amyloidosis (AL). Journal of Clinical Oncology. 35: 8047-8047. DOI: 10.1200/Jco.2017.35.15_Suppl.8047 |
0.387 |
|
| 2017 |
Lakshman A, Abeykoon JP, Kumar S, Rajkumar S, Kourelis T, Buadi F, Dingli D, Lacy M, Gonsalves WI, Dispenzieri A, Kyle RA, Lin Y, Go RS, Warsame RM, Hayman SR, et al. Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM). Journal of Clinical Oncology. 35: 8038-8038. DOI: 10.1200/Jco.2017.35.15_Suppl.8038 |
0.364 |
|
| 2017 |
Gonsalves WI, Rajkumar SV, Dispenzieri A, Lacy M, Buadi F, Dingli D, Go RS, Kapoor P, Hayman SR, Lust JA, Leung N, Russell SJ, Zeldenrust SR, Lin Y, Hwa YL, et al. The impact of body mass index on the risk of early progression of smoldering multiple myeloma to symptomatic myeloma. Journal of Clinical Oncology. 35: 8032-8032. DOI: 10.1200/Jco.2017.35.15_Suppl.8032 |
0.372 |
|
| 2017 |
Lakshman A, Alhaj Moustafa M, Rajkumar S, Dispenzieri A, Gertz MA, Buadi F, Lacy M, Dingli D, Hayman SR, Gonsalves WI, Kapoor P, Leung N, Lin Y, Go RS, Kourelis T, et al. Natural history of t(11;14) multiple myeloma (MM). Journal of Clinical Oncology. 35: 8014-8014. DOI: 10.1200/Jco.2017.35.15_Suppl.8014 |
0.395 |
|
| 2017 |
Orme J, Go RS, Kumar SK, Dispenzieri A, Gertz MA, Buadi FK, Dingli D, Leung N, Lacy MQ, Kapoor P, Lust JA, Lin Y, Russell SJ, Hayman SR, Zeldenrust S, ... ... Rajkumar SV, et al. Disparities in Outcomes of Patients with Multiple Myeloma Based on Geographic Distance from NCI-Designated Cancer Centers: A SEER Based Analysis Blood. 130: 4689-4689. DOI: 10.1182/Blood.V130.Suppl_1.4689.4689 |
0.304 |
|
| 2017 |
Muchtar E, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, Buadi FK, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves WI, Kourelis T, Warsame R, ... ... Rajkumar SV, et al. What Does AL Amyloidosis Look like in the Era of Mass Spectrometry Typing Blood. 130: 4353-4353. DOI: 10.1182/Blood.V130.Suppl_1.4353.4353 |
0.353 |
|
| 2017 |
Abeykoon JP, Zanwar S, Kumar SK, Gertz MA, Choong G, Winters JL, Rajkumar SV, Go RS, Habermann TM, Lacy MQ, Witzig TE, Dingli D, Dispenzieri A, Johnston PB, Leung N, et al. Predictors of Hyperviscosity Syndrome (HVS) in Waldenström Macroglobulinemia (WM) Blood. 130: 4022-4022. DOI: 10.1182/Blood.V130.Suppl_1.4022.4022 |
0.362 |
|
| 2017 |
Muchtar E, Dispenzieri A, Lacy MQ, Leung N, Buadi FK, Grogan M, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Chakraborty R, Gonsalves WI, Kourelis T, Warsame R, ... ... Rajkumar SV, et al. Depth of Organ Response in Newly Diagnosed AL Amyloidosis Is Associated with Improved Survival: Improved Outcome Discrimination with Graded Organ Response Blood. 130: 3154-3154. DOI: 10.1182/Blood.V130.Suppl_1.3154.3154 |
0.394 |
|
| 2017 |
Paquin A, Kumar SK, Buadi FK, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman SR, Zeldenrust S, Lust JA, Russell SJ, Leung N, ... ... Rajkumar SV, et al. Overall Survival of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma: Comparative Effectiveness Analysis of Modern Induction Regimens on Outcome Blood. 130: 3138-3138. DOI: 10.1182/Blood.V130.Suppl_1.3138.3138 |
0.465 |
|
| 2017 |
Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder A, Hayman SR, Hobbs M, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, ... ... Rajkumar SV, et al. Composite Organ and Hematologic Response Model Risk Stratifies Patients with Light Chain Amyloidosis Blood. 130: 3046-3046. DOI: 10.1182/Blood.V130.Suppl_1.3046.3046 |
0.311 |
|
| 2017 |
Warsame R, Laplant B, Laumann K, Kumar SK, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, Buadi FK, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, ... ... Rajkumar SV, et al. Long-Term Outcomes of IMiD Based Trials in Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Pooled Analysis Blood. 130: 1833-1833. DOI: 10.1182/Blood.V130.Suppl_1.1833.1833 |
0.458 |
|
| 2017 |
Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi F, Lacy M, Dingli D, Fonder A, Hayman S, Hobbs M, Gonsalves W, Hwa YL, Kapoor P, Kyle R, Leung N, ... ... Rajkumar S, et al. Bortezomib Versus Non-Bortezomib Based Initial Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis Clinical Lymphoma Myeloma and Leukemia. 17: e140-e141. DOI: 10.1016/J.Clml.2017.03.254 |
0.342 |
|
| 2016 |
Landgren O, Rajkumar SV. New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma. Clinical Cancer Research. 22: 5428-5433. PMID 28151710 DOI: 10.1158/1078-0432.Ccr-16-0866 |
0.432 |
|
| 2016 |
Rajan AM, Rajkumar SV. Treatment of newly diagnosed myeloma: Bortezomib-based triplet. Seminars in Oncology. 43: 700-702. PMID 28061990 DOI: 10.1053/J.Seminoncol.2016.11.003 |
0.404 |
|
| 2016 |
Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet (London, England). PMID 28017406 DOI: 10.1016/S0140-6736(16)31594-X |
0.423 |
|
| 2016 |
Muchtar E, Jevremovic D, Dispenzieri A, Dingli D, Buadi FK, Lacy MQ, Gonsalves W, Hayman SR, Kapoor P, Leung N, Russell S, Lust JA, Lin Y, Go RS, Chakraborty R, ... ... Rajkumar SV, et al. The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first line treatment. Blood. PMID 27729322 DOI: 10.1182/Blood-2016-06-721878 |
0.417 |
|
| 2016 |
Rajkumar SV, Kyle RA. Progress in Myeloma - A Monoclonal Breakthrough. The New England Journal of Medicine. 375: 1390-1392. PMID 27705251 DOI: 10.1056/Nejme1609835 |
0.352 |
|
| 2016 |
Kumar SK, LaPlant BR, Reeder CB, Roy V, Halvorson AE, Buadi F, Gertz MA, Bergsagel PL, Dispenzieri A, Thompson MA, Crawley J, Kapoor P, Mikhael J, Stewart K, Hayman SR, ... ... Rajkumar SV, et al. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood. PMID 27702799 DOI: 10.1182/Blood-2016-05-717769 |
0.383 |
|
| 2016 |
Biran N, Jacobus S, Vesole DH, Callander NS, Fonseca R, Williams ME, Abonour R, Katz MS, Rajkumar SV, Greipp PR, Siegel DS. Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up. Blood Cancer Journal. 6: e466. PMID 27588519 DOI: 10.1038/bcj.2016.68 |
0.336 |
|
| 2016 |
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, ... ... Rajkumar SV, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. The Lancet. Oncology. 17: e328-46. PMID 27511158 DOI: 10.1016/S1470-2045(16)30206-6 |
0.353 |
|
| 2016 |
Milani P, Rajkumar SV, Merlini G, Kumar S, Gertz MA, Palladini G, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Kapoor P, Go RS, et al. N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. American Journal of Hematology. PMID 27508522 DOI: 10.1002/Ajh.24532 |
0.396 |
|
| 2016 |
Ramakrishnan V, Gomez M, Prasad V, Kimlinger T, Painuly U, Mukhopadhyay B, Haug J, Bi L, Rajkumar SV, Kumar S. Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma. Oncotarget. PMID 27494845 DOI: 10.18632/Oncotarget.11028 |
0.315 |
|
| 2016 |
Muchtar E, Dispenzieri A, Kumar SK, Dingli D, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Leung N, Chakraborty R, Russel S, Lust JA, Lin Y, Go RS, Zeldenrust S, ... ... Rajkumar SV, et al. Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. Haematologica. PMID 27479823 DOI: 10.3324/Haematol.2016.147041 |
0.435 |
|
| 2016 |
Gonsalves WI, Rajkumar SV, Dispenzieri A, Dingli D, Timm MM, Morice WG, Lacy MQ, Buadi FK, Go RS, Leung N, Kapoor P, Hayman SR, Lust JA, Russell SJ, Zeldenrust SR, et al. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia. PMID 27457702 DOI: 10.1038/leu.2016.205 |
0.343 |
|
| 2016 |
Muchtar E, Dingli D, Kumar S, Buadi FK, Dispenzieri A, Hayman SR, Wolf RC, Gastineau DA, Chakraborty R, Hogan WJ, Leung N, Kapoor P, Lacy MQ, Rajkumar SV, Gertz MA. Autologous stem cell transplant for multiple myeloma patients 70 years or older. Bone Marrow Transplantation. PMID 27376447 DOI: 10.1038/bmt.2016.174 |
0.302 |
|
| 2016 |
Hwa YL, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Kourelis TV, Gonsalves WI, Rajkumar SV, Go RS, Leung N, Kapoor P, Dingli D, Kyle RA, Russell S, Lust JA, et al. Induction Therapy Pre-Autologous Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis: A Retrospective Evaluation. American Journal of Hematology. PMID 27341539 DOI: 10.1002/Ajh.24453 |
0.448 |
|
| 2016 |
Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. American Journal of Hematology. 91: 719-34. PMID 27291302 DOI: 10.1002/Ajh.24402 |
0.456 |
|
| 2016 |
Gonsalves WI, Timm MM, Rajkumar SV, Morice WG, Dispenzieri A, Buadi FK, Lacy MQ, Dingli D, Leung N, Kapoor P, Kyle RA, Gertz MA, Kumar SK. The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. Leukemia Research. 44: 32-39. PMID 26994849 DOI: 10.1016/J.Leukres.2016.03.003 |
0.315 |
|
| 2016 |
Kourelis TV, Buadi FK, Kumar SK, Gertz MA, Lacy MQ, Dingli D, Go RS, Kapoor P, Lust JA, Hayman SR, Hwa Y, Rajkumar SV, Zeldenrust SR, Russell SJ, Lin Y, et al. Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. American Journal of Hematology. PMID 26972803 DOI: 10.1002/Ajh.24356 |
0.377 |
|
| 2016 |
Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, et al. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. Blood Cancer Journal. 6: e401. PMID 26967818 DOI: 10.1182/Blood.V126.23.4176.4176 |
0.42 |
|
| 2016 |
Mullikin TC, Rajkumar SV, Dispenzieri A, Buadi FK, Lacy MQ, Lin Y, Dingli D, Go RS, Hayman SR, Zeldenrust SR, Russell SJ, Lust JA, Leung N, Kapoor P, Kyle RA, et al. Clinical characteristics and outcomes in biclonal gammopathies. American Journal of Hematology. PMID 26840395 DOI: 10.1002/Ajh.24319 |
0.364 |
|
| 2016 |
Rajkumar SV. Daratumumab in multiple myeloma. Lancet (London, England). 387: 1490-2. PMID 26778537 DOI: 10.1016/S0140-6736(15)01226-X |
0.328 |
|
| 2016 |
Rajkumar SV, Kumar S. Multiple Myeloma: Diagnosis and Treatment. Mayo Clinic Proceedings. 91: 101-19. PMID 26763514 DOI: 10.1016/J.Mayocp.2015.11.007 |
0.328 |
|
| 2016 |
Rajkumar SV. Myeloma today: Disease definitions and treatment advances. American Journal of Hematology. 91: 90-100. PMID 26565896 DOI: 10.1002/Ajh.24236 |
0.369 |
|
| 2016 |
Tandon N, Lacy M, Buadi F, Leung N, Go RS, Dingli D, Kapoor P, Gertz MA, Lin Y, Dispenzieri A, Drake M, Hwa YL, Fonder A, Hobbs M, Hayman SR, ... ... Rajkumar S, et al. Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma. Journal of Clinical Oncology. 34: 8053-8053. DOI: 10.1200/Jco.2016.34.15_Suppl.8053 |
0.36 |
|
| 2016 |
Ravindran A, Bartley AC, Ashrani AA, Gonsalves WI, Hashmi SK, Kapoor P, Marshall AL, Siddiqui MA, Dispenzieri A, Kyle RA, Rajkumar S, Go RS. Prevalence and survival of smoldering multiple myeloma in the US: Analysis using a national dataset. Journal of Clinical Oncology. 34: 8035-8035. DOI: 10.1200/Jco.2016.34.15_Suppl.8035 |
0.314 |
|
| 2016 |
Richardson PG, Avet-Loiseau H, Palumbo A, Viterbo L, Nagler A, Ganly P, Ben Yehuda D, San Miguel J, Rajkumar S, Pour L, Langer C, Bahlis NJ, Pluta A, Masszi T, Berg D, et al. Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study. Journal of Clinical Oncology. 34: 8018-8018. DOI: 10.1200/Jco.2016.34.15_Suppl.8018 |
0.358 |
|
| 2016 |
Tandon N, Rajkumar S, Lacy M, Dispenzieri A, Buadi F, Gertz MA, Hayman SR, Leung N, Go RS, Dingli D, Kapoor P, Lin Y, Hwa YL, Fonder A, Hobbs M, et al. Clinical utility of the revised international staging system (RISS) in newly diagnosed multiple myeloma. Journal of Clinical Oncology. 34: 8017-8017. DOI: 10.1200/Jco.2016.34.15_Suppl.8017 |
0.304 |
|
| 2016 |
Gonsalves WI, Rajkumar SV, Timm M, Morice W, Dispenzieri A, Lacy M, Buadi F, Dingli D, Go RS, Leung N, Kapoor P, Hayman SR, Lust JA, Russell S, Zeldenrust SR, et al. Quantification of circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) to identify patients with smoldering multiple myeloma (SMM) at high risk of progression. Journal of Clinical Oncology. 34: 8015-8015. DOI: 10.1200/Jco.2016.34.15_Suppl.8015 |
0.37 |
|
| 2016 |
Ravi PK, Kumar S, Larsen JT, Gonsalves WI, Buadi F, Lacy M, Go RS, Dispenzieri A, Kapoor P, Lust JA, Gertz MA, Kyle RA, Rajkumar SV. Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM). Journal of Clinical Oncology. 34: 8004-8004. DOI: 10.1200/Jco.2016.34.15_Suppl.8004 |
0.324 |
|
| 2016 |
Lacy M, Bergsagel PL, LaPlant B, Halvorson A, Buadi F, Leung N, Go RS, Dingli D, Kapoor P, Gertz MA, Lin Y, Dispenzieri A, Hwa YL, Fonder A, Fonseca R, ... ... Rajkumar SV, et al. Phase 1/2 trial of ixazomib, cyclophosphamide, and dexamethasone for newly diagnosed multiple myeloma (NDMM). Journal of Clinical Oncology. 34: 8002-8002. DOI: 10.1200/Jco.2016.34.15_Suppl.8002 |
0.364 |
|
| 2016 |
Mikhael J, Manola J, Lonial S, Weiss BM, Oettel K, Hayman SR, Kanate AS, Rajkumar SV. Lenalidomide and Low Dose Dexamethasone in Previously Treated Multiple Myeloma Patients with Impaired Renal Function: Efficacy Analysis of PrE1003, a Precog Study Blood. 128: 5712-5712. DOI: 10.1182/Blood.V128.22.5712.5712 |
0.42 |
|
| 2016 |
Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, et al. Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma Blood. 128: 5615-5615. DOI: 10.1182/Blood.V128.22.5615.5615 |
0.395 |
|
| 2016 |
Abeykoon JP, Hobbs M, Paludo J, Larson DR, Dispenzieri A, Gertz MA, Baudi FK, Rajkumar SV, Dingli D, Gonsalves WI, Leung N, Kyle RA, Lacy MQ, Hayman SR, Kourelis T, et al. Outcome of Very Young (≤ 40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study Blood. 128: 5576-5576. DOI: 10.1182/Blood.V128.22.5576.5576 |
0.359 |
|
| 2016 |
Tandon N, Sidana S, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder A, Hayman SR, Hobbs M, Kapoor P, Gonsalves WI, Hwa YL, Kyle RA, Go RS, ... ... Rajkumar SV, et al. Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage Blood. 128: 4627-4627. DOI: 10.1182/Blood.V128.22.4627.4627 |
0.436 |
|
| 2016 |
Clay AI, Rishi A, Kumar S, Rajkumar SV, Greenberg AJ, Larson DR, O'Byrne MM, Slager SL, Vachon CM. Risk of Monoclonal Gammopathy of Undetermined Significance in First-Degree Relatives of Multiple Myeloma Cases By Cytogenetic Subtype Blood. 128: 4425-4425. DOI: 10.1182/Blood.V128.22.4425.4425 |
0.673 |
|
| 2016 |
Hwa YL, Warsame R, Gertz MA, Buadi FK, Lacy MQ, Kumar S, Dingli D, Zeldenrust SR, Leung N, Hayman SR, Kapoor P, Gonsalves WI, Kourelis T, Russell SJ, Go RS, ... ... Rajkumar SV, et al. Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis Blood. 128: 3444-3444. DOI: 10.1182/Blood.V128.22.3444.3444 |
0.369 |
|
| 2016 |
Tandon N, Sidana S, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Fonder A, Hobbs M, Hayman SR, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, ... ... Rajkumar SV, et al. Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis Blood. 128: 3338-3338. DOI: 10.1182/Blood.V128.22.3338.3338 |
0.407 |
|
| 2016 |
Hobbs M, Paludo J, Fonder A, Abeykoon JP, Gertz MA, Rajkumar SV, Go RS, Buadi FK, Lacy MQ, Leung N, Dispenzieri A, Gonsalves WI, Dingli D, Hwa YL, Kourelis T, et al. Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting Blood. 128: 3337-3337. DOI: 10.1182/Blood.V128.22.3337.3337 |
0.459 |
|
| 2016 |
Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi F, Lacy MQ, Dingli D, Fonder A, Hayman SR, Hobbs M, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, ... ... Rajkumar SV, et al. Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis Blood. 128: 3317-3317. DOI: 10.1182/Blood.V128.22.3317.3317 |
0.433 |
|
| 2016 |
Hwa YL, Shi Q, Kumar S, Lacy MQ, Gertz MA, Kapoor P, Buadi FK, Leung N, Dingli D, Go RS, Hayman SR, Gonsalves WI, Russell SJ, Lust JA, Lin Y, ... Rajkumar SV, et al. Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation Blood. 128: 3306-3306. DOI: 10.1182/Blood.V128.22.3306.3306 |
0.359 |
|
| 2016 |
Muchtar E, Dean D, Dispenzieri A, Dingli D, Buadi FK, Lacy MQ, Gonsalves WI, Hayman SR, Kapoor P, Leung N, Russell SJ, Lust JA, Go RS, Lin Y, Chakraborty R, ... ... Rajkumar SV, et al. Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden Blood. 128: 3273-3273. DOI: 10.1182/Blood.V128.22.3273.3273 |
0.368 |
|
| 2016 |
Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder A, Hayman SR, Hobbs M, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, ... ... Rajkumar SV, et al. Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis Blood. 128: 3272-3272. DOI: 10.1182/Blood.V128.22.3272.3272 |
0.421 |
|
| 2016 |
Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, et al. Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents Blood. 128: 3255-3255. DOI: 10.1182/Blood.V128.22.3255.3255 |
0.436 |
|
| 2016 |
Ravi P, Kumar S, Gonsalves WI, Buadi FK, Lacy MQ, Go RS, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, Kyle RA, ... ... Rajkumar SV, et al. Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy Blood. 128: 3251-3251. DOI: 10.1182/Blood.V128.22.3251.3251 |
0.415 |
|
| 2016 |
Paludo J, Abeykoon JP, Shreders A, Ailawadhi S, Gertz MA, Reeder CB, King RL, Leung N, Kumar S, Kyle RA, Buadi FK, Habermann TM, Dingli D, Witzig TE, Dispenzieri A, ... ... Rajkumar SV, et al. Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia Blood. 128: 2972-2972. DOI: 10.1182/Blood.V128.22.2972.2972 |
0.414 |
|
| 2016 |
Paludo J, Abeykoon JP, Hesse AB, Shreders A, Ailawadhi S, Ansell S, Gertz MA, Reeder CB, King RL, Kyle RA, Buadi FK, Dispenzieri A, Lacy MQ, Habermann TM, Dingli D, ... ... Rajkumar SV, et al. Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM) Blood. 128: 2968-2968. DOI: 10.1182/Blood.V128.22.2968.2968 |
0.411 |
|
| 2016 |
Abeykoon JP, Paludo J, Kapoor P, Gonsalves WI, Gertz MA, Ansell S, He R, Go RS, Baudi FK, Rajkumar SV, Kumar S, King RL. Clinical Presentation and Outcome of Patients with Myeloid Differentiation Factor 88 Gene (MYD88) Wild-Type Waldenstrom Macroglobulinemia Blood. 128: 2960-2960. DOI: 10.1182/Blood.V128.22.2960.2960 |
0.445 |
|
| 2016 |
Di Bacco A, Bahlis NJ, Munshi NC, Avet-Loiseau H, Masszi T, Viterbo L, Pour L, Ganly P, Cavo M, Langer C, Kumar S, Rajkumar SV, Berg D, Lin J, Li B, et al. Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM) Blood. 128: 243-243. DOI: 10.1182/Blood.V128.22.243.243 |
0.354 |
|
| 2016 |
Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder A, Hayman SR, Hobbs M, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, ... ... Rajkumar SV, et al. Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis Blood. 128: 2187-2187. DOI: 10.1182/Blood.V128.22.2187.2187 |
0.419 |
|
| 2016 |
Tandon N, Sidana S, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Fonder A, Hayman SR, Hobbs M, Gonsalves WI, Kapoor P, Hwa YL, Kyle RA, Leung N, ... ... Rajkumar SV, et al. Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis Blood. 128: 2082-2082. DOI: 10.1182/Blood.V128.22.2082.2082 |
0.436 |
|
| 2016 |
Paludo J, Vallumsetla N, Ansell S, Swaika A, Jain T, Ailawadhi S, Reeder CB, Kumar S, Habermann TM, Witzig TE, Go RS, Buadi FK, Gonsalves WI, Dispenzieri A, Lacy MQ, ... ... Rajkumar SV, et al. Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience Blood. 128: 1810-1810. DOI: 10.1182/Blood.V128.22.1810.1810 |
0.413 |
|
| 2016 |
Ghosh T, Gonsalves WI, Jevremovic D, Rajkumar SV, Timm MM, Morice W, Dispenzieri A, Dingli D, Kapoor P, Kourelis T, Lacy MQ, Hayman SR, Buadi FK, Leung N, Go RS, et al. The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma Blood. 128: 1194-1194. DOI: 10.1182/Blood.V128.22.1194.1194 |
0.405 |
|
| 2016 |
Ailawadhi S, Jacobus SJ, Sexton R, Stewart AK, Dispenzieri A, Hussein MA, Zonder J, Crowley J, Hoering A, Barlogie B, Orlowski RZ, Rajkumar SV. Disease and Outcome Disparities in Multiple Myeloma (MM): Exploring the Role of Race/Ethnicity and Obesity in Cooperative Group Clinical Trials Blood. 128: 1192-1192. DOI: 10.1182/Blood.V128.22.1192.1192 |
0.361 |
|
| 2015 |
Rajkumar SV. Evolving diagnostic criteria for multiple myeloma. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2015: 272-8. PMID 26637733 DOI: 10.1182/Asheducation-2015.1.272 |
0.402 |
|
| 2015 |
Rajkumar SV, Richardson P, San Miguel JF. Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood. 126: 921-2. PMID 26272048 DOI: 10.1182/Blood-2015-05-647636 |
0.339 |
|
| 2015 |
Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, ... ... Rajkumar SV, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26240224 DOI: 10.1200/Jco.2015.61.2267 |
0.345 |
|
| 2015 |
Kyle RA, Rajkumar SV. Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. Jama Oncology. 1: 174-5. PMID 26181018 DOI: 10.1001/Jamaoncol.2015.33 |
0.34 |
|
| 2015 |
Stewart AK, Jacobus S, Fonseca R, Weiss M, Callander NS, Chanan-Khan AA, Rajkumar SV. Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood. 126: 1294-301. PMID 26157076 DOI: 10.1182/Blood-2014-12-613927 |
0.335 |
|
| 2015 |
Binder M, Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Buadi FK, Dingli D, Hayman SR, Lust JA, Kapoor P, Lin Y, Go RS, Hwa YL, Kyle RA, Kumar SK. Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. American Journal of Hematology. 90: 888-91. PMID 26148022 DOI: 10.1002/Ajh.24107 |
0.352 |
|
| 2015 |
Zand L, Nasr SH, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Kumar S, Kyle RA, Fervenza FC, Sethi S, Dingli D, Rajkumar SV, Kapoor P, McCurdy A, Leung N. Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. Leukemia & Lymphoma. 1-8. PMID 25860232 DOI: 10.3109/10428194.2015.1040011 |
0.347 |
|
| 2015 |
Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 125: 3069-75. PMID 25838344 DOI: 10.1182/Blood-2014-09-568899 |
0.434 |
|
| 2015 |
Gonsalves WI, Leung N, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Kapoor P, Go RS, Lin Y, Russell SJ, Lust JA, Zeldenrust S, Kyle RA, et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer Journal. 5: e296. PMID 25794132 DOI: 10.1038/bcj.2015.20 |
0.382 |
|
| 2015 |
Dispenzieri A, Gertz MA, Saenger A, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Leung N, Zeldenrust S, Hayman SR, Kapoor P, Grogan M, Hwa L, Russell SJ, Go RS, ... Rajkumar SV, et al. Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. American Journal of Hematology. 90: 524-8. PMID 25753178 DOI: 10.1002/Ajh.24001 |
0.346 |
|
| 2015 |
Chawla SS, Kumar SK, Dispenzieri A, Greenberg AJ, Larson DR, Kyle RA, Lacy MQ, Gertz MA, Rajkumar SV. Clinical Course and Prognosis of Non-Secretory Multiple Myeloma. European Journal of Haematology. PMID 25690913 DOI: 10.1111/ejh.12534 |
0.608 |
|
| 2015 |
Greenberg AJ, Philip S, Paner A, Velinova S, Badros A, Catchatourian R, Ketterling R, Kyle RA, Kumar S, Vachon CM, Rajkumar SV. Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study. Blood Cancer Journal. 5: e279. PMID 25679291 DOI: 10.1038/Bcj.2015.8 |
0.61 |
|
| 2015 |
Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, Offidani M, McCarthy P, Evangelista A, Lonial S, Zweegman S, Musto P, Terpos E, Belch A, Hajek R, ... ... Rajkumar SV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 125: 2068-74. PMID 25628469 DOI: 10.1182/Blood-2014-12-615187 |
0.364 |
|
| 2015 |
Greenberg AJ, Philip S, Paner A, Velinova S, Badros A, Catchatourian R, Ketterling R, Kyle RA, Kumar S, Vachon CM, Rajkumar SV. Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study. Blood Cancer Journal. 5: e271. PMID 25555162 DOI: 10.1038/Bcj.2014.91 |
0.616 |
|
| 2015 |
Kaufman GP, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Kapoor P, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, et al. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. American Journal of Hematology. 90: 181-6. PMID 25388651 DOI: 10.1002/Ajh.23898 |
0.346 |
|
| 2015 |
Chawla SS, Kumar SK, Dispenzieri A, Greenberg AJ, Larson DR, Kyle RA, Lacy MQ, Gertz MA, Rajkumar SV. Clinical course and prognosis of non-secretory multiple myeloma. European Journal of Haematology. 95: 57-64. PMID 25382589 DOI: 10.1111/Ejh.12478 |
0.628 |
|
| 2015 |
Safadi S, Dispenzieri A, Amer H, Gertz MA, Rajkumar SV, Hayman SR, Lacy MQ, Leung N. Multiple myeloma after kidney transplantation. Clinical Transplantation. 29: 76-84. PMID 25377159 DOI: 10.1111/Ctr.12482 |
0.309 |
|
| 2015 |
Gertz MA, Lacy M, Dispenzieri A, Buadi F, Dingli D, Hayman SR, Kumar S, Leung N, Lust JA, Rajkumar SV, Russell SJ, Suman V, Hogan WJ. Phase III trial of stem cell transplantation compared to melphalan and dexamethasone in the treatment of immunoglobulin light chain amyloidosis (AL). Journal of Clinical Oncology. 33: 8595-8595. DOI: 10.1200/Jco.2015.33.15_Suppl.8595 |
0.389 |
|
| 2015 |
Alhaj Moustafa M, Rajkumar SV, Dispenzieri A, Lacy M, Gertz MA, Buadi F, Dingli D, Hayman SR, Kapoor P, Hwa YL, Lust JA, Go RS, Kyle RA, Kumar S. Clinical outcomes in t(11;14) multiple myeloma. Journal of Clinical Oncology. 33: 8592-8592. DOI: 10.1200/Jco.2015.33.15_Suppl.8592 |
0.435 |
|
| 2015 |
Larsen JT, Ramakrishnan V, Wellik L, Kimlinger TK, Rajkumar SV, Kumar S. Patterns of AKT, mTOR, ERK, and STAT3 pathway activation in MGUS, smoldering multiple myeloma, and multiple myeloma. Journal of Clinical Oncology. 33: 8589-8589. DOI: 10.1200/Jco.2015.33.15_Suppl.8589 |
0.332 |
|
| 2015 |
Kaufman GP, Gertz MA, Dispenzieri A, Lacy M, Buadi F, Dingli D, Hayman SR, Kapoor P, Rajkumar SV, Kumar S. Outcomes of high, t(11;14), and standard cytogenetic risk multiple myeloma following early high dose therapy and autologous hematopoietic cell transplantation (SCT). Journal of Clinical Oncology. 33: 8583-8583. DOI: 10.1200/Jco.2015.33.15_Suppl.8583 |
0.396 |
|
| 2015 |
Dimopoulos MA, Stewart AK, Rajkumar SV, Masszi T, Oriol A, Hajek R, Rosinol L, Siegel DSD, Mihaylov G, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San Miguel JF, et al. Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391). Journal of Clinical Oncology. 33: 8525-8525. DOI: 10.1200/Jco.2015.33.15_Suppl.8525 |
0.39 |
|
| 2015 |
Facon T, Hulin C, Dimopoulos MA, Belch A, Reece DE, Catalano JV, Pinto A, Ludwig H, Bahlis NJ, Cavo M, Moreau P, Qiu L, LeBlanc R, Schots R, Rajkumar SV, et al. FIRST study: Updated overall survival (OS) in stem cell transplant (SCT)-ineligible newly diagnosed multiple myeloma (NDMM) patients (pts) treated with continuous lenalidomide plus low-dose dexamethasone (Rd) vs melphalan, prednisone, and thalidomide (MPT). Journal of Clinical Oncology. 33: 8524-8524. DOI: 10.1200/Jco.2015.33.15_Suppl.8524 |
0.363 |
|
| 2015 |
Avet-Loiseau H, Hulin C, Benboubker L, Dimopoulos MA, Belch A, Reece D, Catalano J, Pinto A, Ludwig H, Bahlis NJ, Cavo M, Attal M, Moreau P, Qiu L, LeBlanc R, ... ... Rajkumar SV, et al. Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial Blood. 126: 730-730. DOI: 10.1182/Blood.V126.23.730.730 |
0.375 |
|
| 2015 |
Chakraborty R, Gertz MA, Dispenzieri A, Gonsalves WI, Go RS, Hayman SR, Hwa YL, Kapoor P, Kyle RA, Lacy MQ, Leung N, Rajkumar SV, Russell SJ, Zeldenrust SR, Kumar S. Natural History of Amyloidosis Isolated to Fat and Bone Marrow Aspirate Blood. 126: 5303-5303. DOI: 10.1182/Blood.V126.23.5303.5303 |
0.409 |
|
| 2015 |
Mitra AK, Mukherjee U, Harding T, Stessman H, Li Y, Jin J, Kumar SK, Rajkumar SV, Ness BGV. Scattome: A Single-Cell Analysis of Targeted Transcriptome Program to Predict Drug Sensitivity of Single Cells within Human Myeloma Tumors Blood. 126: 4249-4249. DOI: 10.1182/Blood.V126.23.4249.4249 |
0.335 |
|
| 2015 |
Kourelis T, Buadi F, Gertz MA, Kumar S, Lacy MQ, Kapoor P, Go RS, Lust JA, Hayman SR, Rajkumar SV, Zeldenrust SR, Russell SJ, Dingli D, Lin Y, Leung N, et al. Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience Blood. 126: 4197-4197. DOI: 10.1182/Blood.V126.23.4197.4197 |
0.409 |
|
| 2015 |
Warsame R, Kumar S, Thompson CA, Gertz MA, Lacy MQ, Buadi F, Hayman SR, Leung N, Dingli D, Hwa YL, Lust JA, Kapoor P, Lin Y, Go RS, Zeldenrust SR, ... ... Rajkumar SV, et al. AL Amyloidosis and Patient Reported Quality of Life Blood. 126: 3317-3317. DOI: 10.1182/Blood.V126.23.3317.3317 |
0.392 |
|
| 2015 |
Milani P, Gertz MA, Merlini G, Palladini G, Lacy MQ, Baudi FK, Kumar SK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Kapoor P, Go RS, Zeldenrust SR, ... ... Rajkumar SV, et al. N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM) Blood. 126: 3292-3292. DOI: 10.1182/Blood.V126.23.3292.3292 |
0.424 |
|
| 2015 |
Hwa YL, Kumar SK, Lacy MQ, Gertz MA, Buadi F, Rajkumar SV, Go RS, Leung N, Kapoor P, Dingli D, Russell SJ, Lust JA, Hayman SR, Kourelis T, Dispenzieri A. Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant Blood. 126: 3177-3177. DOI: 10.1182/Blood.V126.23.3177.3177 |
0.459 |
|
| 2015 |
Biran N, Jacobus S, Siegel D, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Katz MS, Rajkumar SV, Greipp PR. Outcome with Lenalidomide Plus Dexamethasone Followed By Early Autologous Stem Cell Transplantation in the ECOG-ACRIN E4A03 Randomized Clinical Trial: Long-Term Follow-up Blood. 126: 3174-3174. DOI: 10.1182/Blood.V126.23.3174.3174 |
0.424 |
|
| 2015 |
Kumar SK, Laplant BR, Reeder CB, Roy V, Buadi F, Gertz MA, Laumann K, Bergsagel PL, Dispenzieri A, Kapoor P, Mikhael J, Stewart K, Hayman SR, Hwa YL, Witzig TE, ... ... Rajkumar SV, et al. Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib Blood. 126: 3050-3050. DOI: 10.1182/Blood.V126.23.3050.3050 |
0.433 |
|
| 2015 |
Durie B, Hoering A, Rajkumar SV, Abidi MH, Epstein J, Kahanic SP, Thakuri MC, Reu FJ, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A. Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777 Blood. 126: 25-25. DOI: 10.1182/Blood.V126.23.25.25 |
0.436 |
|
| 2015 |
Higgins L, Go RS, Kumar S, Rajkumar SV, Buadi F, Lacy MQ, Dispenzieri A, Dingli D, Lust JA, Kapoor P, Kyle RA, Gertz MA, Gonsalves WI. Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes Blood. 126: 1830-1830. DOI: 10.1182/Blood.V126.23.1830.1830 |
0.437 |
|
| 2015 |
Milani P, Dispenzieri A, Gertz MA, Lacy MQ, Baudi FK, Kumar SK, Maurer MS, Klarich K, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Kapoor P, Go RS, ... ... Rajkumar SV, et al. In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO) Blood. 126: 1774-1774. DOI: 10.1182/Blood.V126.23.1774.1774 |
0.389 |
|
| 2015 |
Larsen JT, Ramakrishnan V, Haug J, Kimlinger T, Sen S, Mahajan D, Dugar S, Rajkumar SV, Kumar SK. Abstract 2653: Preclinical activity of dual PI3K/mTOR inhibitor SPR965 in multiple myeloma Cancer Research. 75: 2653-2653. DOI: 10.1158/1538-7445.Am2015-2653 |
0.308 |
|
| 2015 |
Gonsalves WI, Leung N, Rajkumar SV, Dispenzieri A, Buadi FK, Lacy MQ, Dingli D, Kapoor P, Lust JA, Go RS, Hayman SR, Lin Y, Zeldenrust S, Kyle RA, Gertz MA, et al. The Reversal of Renal Impairment and its Impact on Survival in Newly Diagnosed Multiple Myeloma Patients Clinical Lymphoma Myeloma and Leukemia. 15: S239. DOI: 10.1016/J.Clml.2015.04.137 |
0.381 |
|
| 2015 |
Gonsalves WI, Gertz M, Dispenzieri A, Lacy M, Buadi F, Dingli D, Hayman S, Kapoor P, Rajkumar SV, Kumar S. Predictors of Survival in Multiple Myeloma Patients after Relapse from a Delayed Autologous Stem Cell Transplant Biology of Blood and Marrow Transplantation. 21: S137. DOI: 10.1016/J.Bbmt.2014.11.188 |
0.371 |
|
| 2014 |
Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Melton LJ, Benson JT, Kumar S, Rajkumar SV. Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. The Lancet. Haematology. 1: e28-e36. PMID 25530988 DOI: 10.1016/S2352-3026(14)70001-8 |
0.329 |
|
| 2014 |
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet. Oncology. 15: e538-48. PMID 25439696 DOI: 10.1016/S1470-2045(14)70442-5 |
0.373 |
|
| 2014 |
Kourelis TV, Kumar SK, Go RS, Kapoor P, Kyle RA, Buadi FK, Gertz MA, Lacy MQ, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Zeldenrust SR, Rajkumar SV, et al. Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. American Journal of Hematology. 89: 1051-4. PMID 25111004 DOI: 10.1002/Ajh.23827 |
0.326 |
|
| 2014 |
Gonsalves WI, Rajkumar SV, Go RS, Dispenzieri A, Gupta V, Singh PP, Buadi FK, Lacy MQ, Kapoor P, Dingli D, Lust JA, Zeldenrust SR, Hayman SR, Kyle RA, Gertz MA, et al. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood. 124: 907-12. PMID 24957143 DOI: 10.1182/Blood-2014-03-565051 |
0.389 |
|
| 2014 |
Gonsalves WI, Rajkumar SV, Gupta V, Morice WG, Timm MM, Singh PP, Dispenzieri A, Buadi FK, Lacy MQ, Kapoor P, Gertz MA, Kumar SK. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia. 28: 2060-5. PMID 24618735 DOI: 10.1038/leu.2014.98 |
0.317 |
|
| 2014 |
Warsame R, Bang SM, Kumar SK, Gertz MA, Lacy MQ, Buadi F, Dingli D, Hayman SR, Kapoor P, Kyle RA, Leung N, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, ... Rajkumar SV, et al. Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. European Journal of Haematology. 92: 485-90. PMID 24502602 DOI: 10.1111/Ejh.12282 |
0.348 |
|
| 2014 |
Landgren O, Graubard BI, Katzmann JA, Kyle RA, Ahmadizadeh I, Clark R, Kumar SK, Dispenzieri A, Greenberg AJ, Therneau TM, Melton LJ, Caporaso N, Korde N, Roschewski M, Costello R, ... ... Rajkumar SV, et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia. 28: 1537-42. PMID 24441287 DOI: 10.1038/Leu.2014.34 |
0.607 |
|
| 2014 |
Kourelis TV, Kumar SK, Srivastava G, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Zeldenrust SR, Leung N, Kyle RA, Russell SJ, Dingli D, Lust JA, Lin Y, Kapoor P, ... ... Rajkumar SV, et al. Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. American Journal of Hematology. 89: 302-5. PMID 24265187 DOI: 10.1002/Ajh.23634 |
0.397 |
|
| 2014 |
Farr JN, Zhang W, Kumar SK, Jacques RM, Ng AC, McCready LK, Rajkumar SV, Drake MT. Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance. Blood. 123: 647-9. PMID 24227822 DOI: 10.1182/Blood-2013-05-505776 |
0.307 |
|
| 2014 |
Schuster SR, Kortuem KM, Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Ahmann G, Kumar S, Rajkumar SV, Mikhael J, Laplant B, Champion MD, Laumann K, Barlogie B, et al. The clinical significance of cereblon expression in multiple myeloma. Leukemia Research. 38: 23-8. PMID 24129344 DOI: 10.1016/J.Leukres.2013.08.015 |
0.384 |
|
| 2014 |
Greenberg AJ, Rajkumar SV, Therneau TM, Singh PP, Dispenzieri A, Kumar SK. Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia. 28: 398-403. PMID 24005246 DOI: 10.1038/leu.2013.258 |
0.609 |
|
| 2014 |
Usmani SZ, Hoering A, Sexton R, Ailawadhi S, Shah JJ, Fredette S, Durie BG, Zonder JA, Dhodapkar MV, Rajkumar SV, Mahindra AK, Zimmerman TM, Richardson PG, Orlowski RZ. SWOG 1211: A randomized phase I/II study of optimal induction therapy for newly diagnosed high-risk multiple myeloma (HRMM). Journal of Clinical Oncology. 32: TPS8624-TPS8624. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps8624 |
0.43 |
|
| 2014 |
Larsen JT, Kumar S, Gonsalves WI, Gupta V, Esplin BL, Ketterling RP, Morice W, Kyle RA, Dispenzieri A, Rajkumar SV. Free light chain assay and cytogenetic abnormalities for identification of high-risk smoldering myeloma. Journal of Clinical Oncology. 32: 8595-8595. DOI: 10.1200/Jco.2014.32.15_Suppl.8595 |
0.379 |
|
| 2014 |
Kumar S, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari PN, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Hui A, Rajkumar SV, et al. Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results Blood. 124: 82-82. DOI: 10.1182/Blood.V124.21.82.82 |
0.357 |
|
| 2014 |
Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, et al. Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study Blood. 124: 79-79. DOI: 10.1182/Blood.V124.21.79.79 |
0.381 |
|
| 2014 |
Mullikin TC, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Buadi F, Kapoor P, Katzmann JA, Larson D, Kyle R, Kumar S. Progression and Outcome in Patients with Biclonal Gammopathies Blood. 124: 5699-5699. DOI: 10.1182/Blood.V124.21.5699.5699 |
0.428 |
|
| 2014 |
Lacy MQ, LaPlant BR, Laumann KM, Kumar S, Gertz MA, Hayman SR, Buadi F, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell S, Dingli D, Go RS, Gonsalves WI, ... ... Rajkumar SV, et al. Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Lenalidomide Refractory Myeloma: Long Term Follow up and Comparison of 2 Mg Vs 4 Mg Doses Blood. 124: 4780-4780. DOI: 10.1182/Blood.V124.21.4780.4780 |
0.362 |
|
| 2014 |
Usmani SZ, Sexton R, Ailawadhi S, Shah JJ, Callander NS, Zimmerman T, Valent J, Rosenzweig M, Lipe BC, Zonder J, Fredette S, Durie BGM, Hoering A, Rajkumar SV, Richardson PG, et al. SWOG 1211: Initial Report on PHASE I Trial of RVD-Elotuzumab for NEWLY Diagnosed High Risk Multiple Myeloma (HRMM) Blood. 124: 4762-4762. DOI: 10.1182/Blood.V124.21.4762.4762 |
0.394 |
|
| 2014 |
Hwa YL, Lacy MQ, Gertz MA, Buadi F, Rajkumar SV, Kumar S, Kapoor P, Go RS, Hayman SR, Lin Y, Lust JA, Dingli D, Russell SJ, Gonsalves WI, Dispenzieri A. Impact of Beta Blocker on Clinical Outcomes of Multiple Myeloma (MM) Patients Blood. 124: 4751-4751. DOI: 10.1182/Blood.V124.21.4751.4751 |
0.333 |
|
| 2014 |
Kaufman GP, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Rajkumar SV, Kumar S. Adverse Cytogenetics, with or without Trisomies, in Patients Undergoing High Dose Therapy for Multiple Myeloma and Impact of Post-Transplant Maintenance Therapy Blood. 124: 3456-3456. DOI: 10.1182/Blood.V124.21.3456.3456 |
0.373 |
|
| 2014 |
Alhaj Moustafa M, Rajkumar SV, Dispenzieri A, Buadi FK, Gertz MA, Lacy MQ, Kapoor P, Hayman SR, Dingli D, Kyle R, Kumar S. Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response Blood. 124: 3427-3427. DOI: 10.1182/Blood.V124.21.3427.3427 |
0.456 |
|
| 2014 |
Paul S, Kochuparambil ST, Thompson CA, Shanafelt TD, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Dingli D, Kapoor P, Hayman SR, Hwa L, Case JK, Rajkumar SV, Kumar S. Quality of Life and Outcomes in Multiple Myeloma Patients Blood. 124: 2605-2605. DOI: 10.1182/Blood.V124.21.2605.2605 |
0.347 |
|
| 2014 |
Paludo J, Vallumsetla N, Kumar S, Ketterling R, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Painuly U, Leung N, Kyle R, Rajkumar SV, Kapoor P. Impact of Novel Agents on Young Patients with t(11;14) Multiple Myeloma Blood. 124: 2059-2059. DOI: 10.1182/Blood.V124.21.2059.2059 |
0.441 |
|
| 2014 |
Kochuparambil ST, Morice WG, Rajkumar SV, Dispenzieri A, Timm MM, Lacy MQ, Gertz MA, Kumar S. Measurement of the Proliferation of Clonal Plasma Cells By Multiparametric Flow Cytometry Is a Clinically Useful Tool in Multiple Myeloma Blood. 124: 2053-2053. DOI: 10.1182/Blood.V124.21.2053.2053 |
0.403 |
|
| 2014 |
Greenberg AJ, Philip S, Paner A, Velinova S, Badros A, Catchatorian R, Larson D, Ketterling R, Kyle RA, Kumar S, Vachon CM, Rajkumar SV. Abstract 272: Evidence of decreased prevalence of the t(11;14) translocation in black patients with multiple myeloma: A multi-center study Cancer Research. 74: 272-272. DOI: 10.1158/1538-7445.Am2014-272 |
0.655 |
|
| 2013 |
Kapoor P, Kumar SK, Dispenzieri A, Lacy MQ, Buadi F, Dingli D, Russell SJ, Hayman SR, Witzig TE, Lust JA, Leung N, Lin Y, Zeldenrust SR, McCurdy A, Greipp PR, ... ... Rajkumar SV, et al. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 4529-35. PMID 24248686 DOI: 10.1200/Jco.2013.49.0086 |
0.301 |
|
| 2013 |
Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Zeldenrust S, Leung N, Kyle RA, Russell S, Dingli D, Lust JA, Lin Y, Kapoor P, Rajkumar SV, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 4319-24. PMID 24145344 DOI: 10.1200/Jco.2013.50.8499 |
0.352 |
|
| 2013 |
Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, et al. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood. 122: 4172-81. PMID 24144641 DOI: 10.1182/Blood-2013-08-520890 |
0.428 |
|
| 2013 |
Burnette BL, Dispenzieri A, Kumar S, Harris AM, Sloan JA, Tilburt JC, Kyle RA, Rajkumar SV. Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies. Cancer. 119: 4308-15. PMID 24105720 DOI: 10.1002/Cncr.28340 |
0.346 |
|
| 2013 |
Rajkumar SV, Kyle RA. Haematological cancer: Treatment of smoldering multiple myeloma. Nature Reviews. Clinical Oncology. 10: 554-5. PMID 23999214 DOI: 10.1038/Nrclinonc.2013.160 |
0.422 |
|
| 2013 |
Leung N, Glavey SV, Kumar S, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, Gertz MA. A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision? Haematologica. 98: 988-92. PMID 23729727 DOI: 10.3324/Haematol.2012.079210 |
0.418 |
|
| 2013 |
Humeniuk MS, Gertz MA, Lacy MQ, Kyle RA, Witzig TE, Kumar SK, Kapoor P, Lust JA, Hayman SR, Buadi FK, Rajkumar SV, Zeldenrust SR, Russell SJ, Dingli D, Lin Y, et al. Outcomes of patients with POEMS syndrome treated initially with radiation. Blood. 122: 68-73. PMID 23699599 DOI: 10.1182/Blood-2013-03-487025 |
0.385 |
|
| 2013 |
Srivastava G, Rana V, Lacy MQ, Buadi FK, Hayman SR, Dispenzieri A, Gertz MA, Dingli D, Zeldenrust S, Russell S, McCurdy A, Kapoor P, Kyle R, Rajkumar SV, Kumar S. Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. Leukemia. 27: 2062-6. PMID 23648667 DOI: 10.1038/leu.2013.143 |
0.347 |
|
| 2013 |
Greenberg AJ, Cousin M, Kumar S, Ketterling RP, Knudson RA, Larson D, Colby C, Scott C, Vachon CM, Rajkumar SV. Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma. European Journal of Haematology. 91: 193-5. PMID 23647020 DOI: 10.1111/Ejh.12133 |
0.646 |
|
| 2013 |
Kyle RA, Therneau TM, Dispenzieri A, Kumar S, Benson JT, Larson DR, Melton LJ, Rajkumar SV. Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemia. Clinical Lymphoma, Myeloma & Leukemia. 13: 184-6. PMID 23490989 DOI: 10.1016/J.Clml.2013.02.005 |
0.37 |
|
| 2013 |
Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. American Journal of Hematology. 88: 226-35. PMID 23440663 DOI: 10.1002/Ajh.23390 |
0.305 |
|
| 2013 |
Baker A, Braggio E, Jacobus S, Jung S, Larson D, Therneau T, Dispenzieri A, Van Wier SA, Ahmann G, Levy J, Perkins L, Kim S, Henderson K, Vesole D, Rajkumar SV, et al. Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood. 121: 3147-52. PMID 23422747 DOI: 10.1182/Blood-2012-07-443606 |
0.37 |
|
| 2013 |
Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia. 27: 941-6. PMID 23183428 DOI: 10.1038/leu.2012.296 |
0.319 |
|
| 2013 |
Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood. 121: 884-92. PMID 23165477 DOI: 10.1182/Blood-2012-05-432203 |
0.411 |
|
| 2013 |
Bang SM, Kyle RA, Rajkumar SV, Kumar S. Treatment patterns and outcomes in elderly patients with multiple myeloma. Leukemia. 27: 971-4. PMID 22948538 DOI: 10.1182/Blood.V118.21.3980.3980 |
0.456 |
|
| 2013 |
Greenberg AJ, Lee AM, Serie DJ, McDonnell SK, Cerhan JR, Liebow M, Larson DR, Colby CL, Norman AD, Kyle RA, Kumar S, Rajkumar SV, Diasio RB, Slager SL, Vachon CM. Single-nucleotide polymorphism rs1052501 associated with monoclonal gammopathy of undetermined significance and multiple myeloma. Leukemia. 27: 515-6. PMID 22945773 DOI: 10.1038/Leu.2012.232 |
0.557 |
|
| 2013 |
Bianchi G, Kyle RA, Larson DR, Witzig TE, Kumar S, Dispenzieri A, Morice WG, Rajkumar SV. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia. 27: 680-5. PMID 22902364 DOI: 10.1038/leu.2012.237 |
0.305 |
|
| 2013 |
Witzig TE, Laumann KM, Lacy MQ, Hayman SR, Dispenzieri A, Kumar S, Reeder CB, Roy V, Lust JA, Gertz MA, Greipp PR, Hassoun H, Mandrekar SJ, Rajkumar SV. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia. 27: 220-5. PMID 22902362 DOI: 10.1038/Leu.2012.236 |
0.332 |
|
| 2013 |
Singh PP, Gonsalves WI, Gupta V, Buadi F, Lacy M, Dispenzieri A, Gertz M, Hayman SR, Dingli D, Russell SJ, Lust JA, Zeldenrust SR, Kapoor P, McCurdy AR, Rajkumar SV, et al. Clinical outcomes after intensive VDT-PACE therapy for relapsed multiple myeloma. Journal of Clinical Oncology. 31: 8600-8600. DOI: 10.1200/Jco.2013.31.15_Suppl.8600 |
0.471 |
|
| 2013 |
Gonsalves WI, Gupta V, Rajkumar SV, Morice WG, Timm MM, Singh PP, Gertz MA, Buadi FK, Lacy MQ, Kapoor P, Dispenzieri A, Kumar SK. Prognostic Value Of Quantifying Circulating Plasma Cells By Multiparametric Flow Cytometry In Patients With Relapsed Multiple Myeloma Blood. 122: 754-754. DOI: 10.1182/Blood.V122.21.754.754 |
0.422 |
|
| 2013 |
Paul Singh P, Kumar SK, LaPlant BR, Gertz MA, Dispenzieri A, Bergsagel PL, Lacy MQ, Singh S, Roy V, Buadi FK, Dingli D, Kyle R, Rajkumar SV, Kapoor P. Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials Blood. 122: 407-407. DOI: 10.1182/Blood.V122.21.407.407 |
0.401 |
|
| 2013 |
Pandey S, Rajkumar SV, Kapoor P, Ketterling RP, Lacy MQ, Gertz MA, Buadi F, Dingli D, Hayman SR, Dispenzieri A, Kumar SK. Impact Of FISH Abnormalities On Response To Lenalidomide In Patients With Multiple Myeloma Blood. 122: 3210-3210. DOI: 10.1182/Blood.V122.21.3210.3210 |
0.463 |
|
| 2013 |
Kumar SK, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille M, Lefebvre P, Cheng WY, Dea K, Yap M, Saravanan S, Pan I, Rembert D, Dhanda R, ... ... Rajkumar SV, et al. Comparable Outcomes With Bortezomib-Cyclophosphamide-Dexamethasone (VCD) and Bortezomib-Lenalidomide-Dexamethasone (VRD) For Initial Treatment Of Newly Diagnosed Multiple Myeloma (MM) Blood. 122: 3178-3178. DOI: 10.1182/Blood.V122.21.3178.3178 |
0.431 |
|
| 2013 |
Lonial S, Jacobus S, Weiss M, Fonseca R, Dhodapkar MV, Rajkumar SV. Phase II Trial Of Initial Safety and Toxicity Prior To The Phase III Trial Of Lenalidomide Versus Observation Alone In Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated By The Eastern Cooperative Oncology Group Blood. 122: 3174-3174. DOI: 10.1182/Blood.V122.21.3174.3174 |
0.444 |
|
| 2013 |
Rajkumar SV, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Hayman SR, Kapoor P, McCurdy A, Leung N, Russell S, Lust JA, Zeldenrust SR, Lin Y, Kyle R, et al. Incidence and Survival Outcomes Of Extramedullary Myeloma Blood. 122: 3141-3141. DOI: 10.1182/Blood.V122.21.3141.3141 |
0.471 |
|
| 2013 |
A Gertz M, Hayman SR, Dingli D, Dispenzieri A, Kapoor P, Kumar SK, Lacy MQ, Leung N, Lin Y, Lust JA, Mikhael JR, Rajkumar SV, Russell SJ, Zeldenrust SR, Kyle R, et al. Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents Blood. 122: 3117-3117. DOI: 10.1182/Blood.V122.21.3117.3117 |
0.468 |
|
| 2013 |
Hwa YL, Laumann KM, LaPlant BR, Buadi F, Dingli D, Dispenzieri A, Gertz MA, Go RS, Hayman SR, Kapoor P, Kumar SK, Leung N, Lin Y, Lust JA, McCurdy A, ... ... Rajkumar SV, et al. Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma Blood. 122: 1979-1979. DOI: 10.1182/Blood.V122.21.1979.1979 |
0.438 |
|
| 2013 |
Greenberg AJ, Walters DK, Arendt BK, Tschumper RC, Kumar SK, Rajkumar SV, Jelinek DF. Responsiveness Of Cytogenetically Discrete Human Myeloma Cell Lines To Lenalidomide: Lack Of Correlation With Cereblon and Interferon Regulatory Factor 4 Expression Levels Blood. 122: 1962-1962. DOI: 10.1182/Blood.V122.21.1962.1962 |
0.613 |
|
| 2013 |
Kumar SK, Roy V, Reeder C, LaPlant BR, Lacy MQ, Gertz MA, Macp, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Hwa L, ... ... Rajkumar SV, et al. Phase 2 Trial Of Single Agent MLN9708 In Patients With Relapsed Multiple Myeloma Not Refractory To Bortezomib Blood. 122: 1944-1944. DOI: 10.1182/Blood.V122.21.1944.1944 |
0.458 |
|
| 2013 |
Mikhael JR, Roy V, Richardson PG, Jakubowiak A, Laumann K, LaPlant BR, Dispenzieri A, Rajkumar SV, Fonseca R, Leung N, Buadi F, Bergsagel PL, Kyle R, Macp, Witzig TE, et al. A Phase I/II Trial Of Pomalidomide, Bortezomib and Dexamethasone In Patients With Relpased Or Refractory Multiple Myeloma Blood. 122: 1940-1940. DOI: 10.1182/Blood.V122.21.1940.1940 |
0.403 |
|
| 2013 |
Gonsalves WI, Gupta V, Rajkumar SV, Morice WG, Timm MM, Singh PP, Dispenzieri A, Buadi FK, Lacy MQ, Kapoor P, Gertz MA, Kumar SK. Increased Circulating Plasma Cells On Multiparametric Flow Cytometry As An Independent Prognostic Biomarker In Newly Diagnosed Multiple Myeloma: Implications For Redefining High-Risk Myeloma Blood. 122: 1842-1842. DOI: 10.1182/Blood.V122.21.1842.1842 |
0.401 |
|
| 2013 |
Baker AS, Braggio E, Jacobus S, Jung S, Larson D, Therneau T, Dispenzieri A, Wier SAV, Ahmann G, Levy J, Perkins L, Kim S, Henderson K, Vesole D, Rajkumar SV, et al. Abstract 2021: Characterization of myeloma tumors from a multi-ethnic cohort using cytogenetics and genomic analysis. Cancer Research. 73: 2021-2021. DOI: 10.1158/1538-7445.Am2013-2021 |
0.338 |
|
| 2013 |
Smeltzer J, Gertz M, Rajkumar SV, Dispenzieri A, Lacy M, Buadi F, Hayman S, Dingli D, Kapoor P, Kumar S. Suppression of Involved Immunoglobulin Free Light Chain Post Therapy and Survival Outcomes Following Autologous Stem Cell Transplantation for Myeloma Biology of Blood and Marrow Transplantation. 19: S156. DOI: 10.1016/J.Bbmt.2012.11.115 |
0.345 |
|
| 2012 |
Rajkumar SV. Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma? Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2012: 354-361. PMID 23233604 DOI: 10.1182/Asheducation.V2012.1.354.3798330 |
0.404 |
|
| 2012 |
Leung N, Gertz M, Kyle RA, Fervenza FC, Irazabal MV, Eirin A, Kumar S, Cha SS, Rajkumar SV, Lacy MQ, Zeldenrust SR, Buadi FK, Hayman SR, Nasr SH, Sethi S, et al. Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases. Clinical Journal of the American Society of Nephrology : Cjasn. 7: 1964-8. PMID 23024162 DOI: 10.2215/Cjn.11161111 |
0.349 |
|
| 2012 |
Murray DL, Seningen JL, Dispenzieri A, Snyder MR, Kyle RA, Rajkumar SV, Katzmann JA. Laboratory persistence and clinical progression of small monoclonal abnormalities. American Journal of Clinical Pathology. 138: 609-13. PMID 23010717 DOI: 10.1309/Ajcpt6Owwmhita1Y |
0.369 |
|
| 2012 |
Rajkumar SV. Second to none Blood. 120: 1537-1539. PMID 22918420 DOI: 10.1182/Blood-2012-07-439158 |
0.332 |
|
| 2012 |
Larson D, Kyle RA, Rajkumar SV. Prevalence and monitoring of oligosecretory myeloma New England Journal of Medicine. 367: 580-581. PMID 22873553 DOI: 10.1056/Nejmc1206740 |
0.358 |
|
| 2012 |
Kapoor P, Ramakrishnan V, Rajkumar SV. Bortezomib combination therapy in multiple myeloma. Seminars in Hematology. 49: 228-42. PMID 22726546 DOI: 10.1053/J.Seminhematol.2012.04.010 |
0.418 |
|
| 2012 |
Rajkumar SV. Haematological cancer: Lenalidomide maintenance-perils of a premature denouement Nature Reviews Clinical Oncology. 9: 372-374. PMID 22665364 DOI: 10.1038/Nrclinonc.2012.100 |
0.325 |
|
| 2012 |
Greenberg AJ, Rajkumar SV, Larson DR, Dispenzieri A, Therneau TM, Colby CL, Phelps TK, Kumar SK, Katzmann JA, Kyle RA, Slager SL, Vachon CM. Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma. British Journal of Haematology. 157: 472-5. PMID 22629552 DOI: 10.1111/J.1365-2141.2012.09075.X |
0.633 |
|
| 2012 |
Warsame R, Gertz MA, Lacy MQ, Kyle RA, Buadi F, Dingli D, Greipp PR, Hayman SR, Kumar SK, Lust JA, Russell SJ, Witzig TE, Mikhael J, Leung N, Zeldenrust SR, ... Rajkumar SV, et al. Trends and outcomes of modern staging of solitary plasmacytoma of bone. American Journal of Hematology. 87: 647-51. PMID 22549792 DOI: 10.1002/Ajh.23201 |
0.383 |
|
| 2012 |
Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, Allred J, Laumann KM, Bergsagel LP, Dingli D, Mikhael JR, Reeder CB, Stewart AK, Zeldenrust SR, Greipp PR, ... ... Rajkumar SV, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 119: 4860-7. PMID 22504925 DOI: 10.1182/Blood-2012-01-407791 |
0.43 |
|
| 2012 |
Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, Dispenzieri A, Kumar S, Rajkumar SV, Carpten JD, Barrett M, Fonseca R, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 120: 1067-76. PMID 22498740 DOI: 10.1182/Blood-2012-01-405985 |
0.369 |
|
| 2012 |
Dispenzieri A, Buadi F, Laumann K, LaPlant B, Hayman SR, Kumar SK, Dingli D, Zeldenrust SR, Mikhael JR, Hall R, Rajkumar SV, Reeder C, Fonseca R, Bergsagel PL, Stewart AK, et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 119: 5397-404. PMID 22493299 DOI: 10.1182/Blood-2012-02-413161 |
0.461 |
|
| 2012 |
Naina HVK, Harris S, Dispenzieri A, Cosio FG, Habermann TM, Stegall MD, Dean PG, Prieto M, Kyle RA, Rajkumar SV, Leung N. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation American Journal of Nephrology. 35: 365-371. PMID 22473253 DOI: 10.1159/000337482 |
0.409 |
|
| 2012 |
Kyle RA, Benson JT, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Melton LJ, Rajkumar SV. Progression in smoldering Waldenstrom macroglobulinemia: long-term results. Blood. 119: 4462-6. PMID 22451426 DOI: 10.1182/Blood-2011-10-384768 |
0.43 |
|
| 2012 |
Moreau P, Rajkumar SV. "Should all eligible patients with multiple myeloma receive autologous stem-cell transplant as part of initial treatment?", Leukemia Research. 36: 677-681. PMID 22430045 DOI: 10.1016/J.Leukres.2012.02.023 |
0.402 |
|
| 2012 |
Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 119: 4375-82. PMID 22422823 DOI: 10.1182/Blood-2011-11-395749 |
0.31 |
|
| 2012 |
Nasr SH, Valeri AM, Sethi S, Fidler ME, Cornell LD, Gertz MA, Lacy M, Dispenzieri A, Rajkumar SV, Kyle RA, Leung N. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 59: 786-94. PMID 22417785 DOI: 10.1053/J.Ajkd.2011.12.028 |
0.314 |
|
| 2012 |
Greenberg AJ, Rajkumar SV. Elucidating disparities across racial and ethnic groups in multiple myeloma patients. International Journal of Hematology. 95: 453-4. PMID 22403056 DOI: 10.1007/S12185-012-1040-Y |
0.659 |
|
| 2012 |
Greenberg AJ, Rajkumar SV, Vachon CM. Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood. 119: 5359-66. PMID 22354002 DOI: 10.1182/Blood-2011-11-387324 |
0.643 |
|
| 2012 |
Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Hayman SR, Buadi FK, Dingli D, Knudson RA, Greenberg A, Russell SJ, Zeldenrust SR, Lust JA, Kyle RA, ... ... Rajkumar SV, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 119: 2100-5. PMID 22234687 DOI: 10.1182/Blood-2011-11-390658 |
0.663 |
|
| 2012 |
Greenberg AJ, Vachon CM, Rajkumar SV. Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia. 26: 609-14. PMID 22193966 DOI: 10.1038/Leu.2011.368 |
0.609 |
|
| 2012 |
Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Halling T, Wellik LE, Witzig TE, Rajkumar SV, Adjei AA, Kumar S. Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. American Journal of Hematology. 87: 277-83. PMID 22190165 DOI: 10.1002/Ajh.22263 |
0.318 |
|
| 2012 |
Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management American Journal of Hematology. 87: 78-88. PMID 22180161 DOI: 10.1002/Ajh.22237 |
0.411 |
|
| 2012 |
Madan S, Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Rajkumar SV, Hogan WJ, Leung N, Grogan M, Gertz MA. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood. 119: 1117-22. PMID 22147893 DOI: 10.1182/Blood-2011-07-370031 |
0.431 |
|
| 2012 |
Gertz MA, Buadi FK, Hayman SR, Dingli D, Dispenzieri A, Greipp PR, Kumar SK, Lacy MQ, Lust JA, Leung N, Rajkumar SV, Russell SJ, Zeldenrust SR, Mikhael JR, Roy V, et al. Immunoglobulin D amyloidosis: a distinct entity. Blood. 119: 44-8. PMID 22065594 DOI: 10.1182/Blood-2011-06-358895 |
0.394 |
|
| 2012 |
Kumar SK, Lacy MQ, Dispenzieri A, Buadi FK, Hayman SR, Dingli D, Gay F, Sinha S, Leung N, Hogan W, Rajkumar SV, Gertz MA. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer. 118: 1585-92. PMID 22009602 DOI: 10.1002/Cncr.26422 |
0.391 |
|
| 2012 |
Sinha S, Lacy M, Mikhael J, Hayman S, Buadi F, Detweiler-Short K, Dispenzieri A, Gertz M, Dingli D, Rajkumar SV, Kumar SK. Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy. Leukemia. 26: 839-41. PMID 21986842 DOI: 10.1182/Blood.V116.21.1965.1965 |
0.473 |
|
| 2012 |
Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, ... ... Rajkumar SV, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 26: 149-57. PMID 21799510 DOI: 10.1038/leu.2011.196 |
0.341 |
|
| 2012 |
Raval GG, Gertz MA, Lacy MQ, Hayman SR, Kumar SK, Buadi FK, Lust JA, Zeldenrust S, Dingli D, Hall RL, Hwa L, Lin Y, Kapoor P, Witzig TE, Kyle RA, ... ... Rajkumar SV, et al. Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis. Blood. 120: 946-946. DOI: 10.1182/Blood.V120.21.946.946 |
0.377 |
|
| 2012 |
Roeker LE, Larson D, Kyle RA, Kumar SK, Dispenzieri A, Rajkumar SV. Development of Myelodysplastic Syndrome and Acute Leukemias in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS): A Population-Based Study of 17,315 Patients Blood. 120: 934-934. DOI: 10.1182/Blood.V120.21.934.934 |
0.412 |
|
| 2012 |
Greenberg A, Cousin M, Vachon CM, Larson D, Colby CL, Kumar SK, Rajkumar SV. Differences in the Distribution of Cytogenetic Subtypes Between Multiple Myeloma Patients with and without a History of Familial MGUS and Multiple Myeloma Blood. 120: 4000-4000. DOI: 10.1182/Blood.V120.21.4000.4000 |
0.651 |
|
| 2012 |
Kumar SK, Dispenzieri A, Gertz MA, Lacy MQ, Lust JA, Hayman SR, Buadi FK, Dingli D, Zeldenrust SR, Russell S, Kapoor P, Lin Y, Hwa L, Larson D, Colby CL, ... ... Rajkumar SV, et al. Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents Blood. 120: 3972-3972. DOI: 10.1182/Blood.V120.21.3972.3972 |
0.421 |
|
| 2012 |
Weiss M, Jacobus S, Abonour R, Anderson KC, Barlogie B, Callander N, Gorak EJ, Hoering A, Kane RC, Katz MS, Matous J, Mills GM, Omel J, Orlowski RZ, Rajkumar SV, et al. Identification of Significant Barriers to Accrual (BtA) to NCI Sponsored Multiple Myeloma – Clinical Trials (MM-CT): A Step towards Improving Accrual to Clinical Trials. Blood. 120: 3165-3165. DOI: 10.1182/Blood.V120.21.3165.3165 |
0.362 |
|
| 2012 |
Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Zeldenrust SR, Ramirez-Alvarado M, Kapoor P, Hogan W, Rajkumar SV, Gertz MA. Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation. Blood. 120: 3138-3138. DOI: 10.1182/Blood.V120.21.3138.3138 |
0.455 |
|
| 2012 |
Lust JA, Usmani SZ, Hamadani M, Barranco C, Lacy MQ, Dispenzieri A, Gertz MA, Dingli D, Russell S, Buadi FK, Zeldenrust SR, Hayman SR, Rajkumar SV, Kumar SK, Thompson J, et al. Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma. Blood. 120: 2973-2973. DOI: 10.1182/Blood.V120.21.2973.2973 |
0.406 |
|
| 2012 |
Ramakrishnan VG, Kimlinger TK, Halling T, Haug J, Painuly U, Rajkumar SV, Kumar SK. Preclinical Evaluation of AT219, a Small Molecule Inhibitor of MDM2 As an Anti-Myeloma Agent. Blood. 120: 2948-2948. DOI: 10.1182/Blood.V120.21.2948.2948 |
0.363 |
|
| 2012 |
Ramakrishnan VG, Kimlinger TK, Painuly U, Haug J, Rajkumar SV, Kumar SK. Simultaneous Inhibition of cIAP1, cIAP2 and XIAP Is Required for Inducing Apoptosis in Multiple Myeloma Cells. Blood. 120: 2943-2943. DOI: 10.1182/Blood.V120.21.2943.2943 |
0.302 |
|
| 2012 |
Burnette BL, Dispenzieri A, Kumar S, Sloan J, Tilburt J, Kyle RA, Rajkumar SV. Treatment Trade-Offs in Myeloma: a Survey of Consecutive Patients Blood. 120: 2059-2059. DOI: 10.1182/Blood.V120.21.2059.2059 |
0.338 |
|
| 2012 |
Lacy MQ, Kumar SK, LaPlant BR, Laumann K, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Russell S, Dingli D, Zeldenrust SR, Fonseca R, Bergsagel P, Stewart K, ... ... Rajkumar SV, et al. Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicing Outcome in 345 Patients Blood. 120: 201-201. DOI: 10.1182/Blood.V120.21.201.201 |
0.422 |
|
| 2012 |
Schuster SR, Kortuem KM, Zhu YX, Braggio E, Shi C, Bruins L, Schmidt J, Ahmann G, Kumar SK, Rajkumar SV, Mikhael JR, Roy V, LaPlant BR, Laumann K, Barlogie B, et al. Cereblon Expression Predicts Response, Progression Free and Overall Survival After Pomalidomide and Dexamethasone Therapy in Multiple Myeloma Blood. 120: 194-194. DOI: 10.1182/Blood.V120.21.194.194 |
0.435 |
|
| 2012 |
Kyle RA, Larson D, Therneau TM, Dispenzieri A, Benson JT, Melton LJ, Rajkumar SV. Idiopathic Bence Jones Proteinuria (Smoldering Monoclonal Light-Chain Proteinuria): Clinical Course and Prognosis Blood. 120: 1861-1861. DOI: 10.1182/Blood.V120.21.1861.1861 |
0.424 |
|
| 2012 |
Warsame R, Bang S, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Lust JA, Russell S, Witzig TE, Kyle RA, Leung N, Zeldenrust SR, Rajkumar SV, Gertz MA, et al. Outcomes and Treatments of Relapsed AL Amyloidosis Following Stem Cell Transplant Blood. 120: 1858-1858. DOI: 10.1182/Blood.V120.21.1858.1858 |
0.453 |
|
| 2012 |
Mikhael JR, Manola J, Dueck AC, Hayman SR, Oettel K, Thompson MA, Kaufman JL, Cescon TP, Rajkumar SV. A Phase I/II Study of the Tolerability of Lenalidomide and Low Dose Dexamethasone in Previously Treated Multiple Myeloma Patients with Impaired Renal Function: Pre1003, a Precog LLC Study Blood. 120: 1856-1856. DOI: 10.1182/Blood.V120.21.1856.1856 |
0.421 |
|
| 2012 |
Painuly U, Ramakrishnan VG, Kimlinger TK, Rajkumar SV, Kumar SK. Promising Pre-Clinical Activity of A-1014907, a Dual Inhibitor of Aurora Kinases and VEGFR in Multiple Myeloma Blood. 120: 1848-1848. DOI: 10.1182/Blood.V120.21.1848.1848 |
0.308 |
|
| 2012 |
Bianchi G, Ramakrishnan VG, Kimlinger TK, Haug J, Rajkumar SV, Kumar S. Abstract 5669: Mechanisms of activity and drug resistance with proteasome inhibitors in multiple myeloma: Comparison of bortezomib and the investigational drug MLN9708 Cancer Research. 72: 5669-5669. DOI: 10.1158/1538-7445.Am2012-5669 |
0.348 |
|
| 2012 |
Greenberg AJ, Rajkumar SV, Larson DR, Dispenzieri A, Therneau TM, Colby CL, Phelps TK, Kumar SK, Katzmann JA, Kyle RA, Slager SL, Vachon CM. Abstract 5485: Increased prevalence of light chain monoclonal gammopathy of undetermined significance (MGUS) in first-degree relatives of individuals with multiple myeloma or MGUS Cancer Research. 72: 5485-5485. DOI: 10.1158/1538-7445.Am2012-5485 |
0.654 |
|
| 2012 |
Baker AS, Braggio E, Jacobus S, Keats J, Jung S, Larson D, Therneau T, Dispenzieri A, Weir SAV, Ahmann G, Henderson K, Rajkumar SV, Jelinek D, Kim S, Carpten J, et al. Abstract 5064: Cytogenetic and somatic characterization of myeloma tumors from a multi-ethnic cohort Cancer Research. 72: 5064-5064. DOI: 10.1158/1538-7445.Am2012-5064 |
0.344 |
|
| 2012 |
Rajkumar SV. Lenalidomide maintenance in myeloma Nature Reviews Clinical Oncology. 9: 605. DOI: 10.1038/Nrclinonc.2012.100-C2 |
0.321 |
|
| 2011 |
Ng AC, Khosla S, Charatcharoenwitthaya N, Kumar SK, Achenbach SJ, Holets MF, McCready LK, Melton LJ, Kyle RA, Rajkumar SV, Drake MT. Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1α levels in patients with MGUS. Blood. 118: 6529-34. PMID 22042700 DOI: 10.1182/Blood-2011-04-351437 |
0.311 |
|
| 2011 |
Jacobus SJ, Kumar S, Uno H, Van Wier SA, Ahmann GJ, Henderson KJ, Callander NS, Williams ME, Siegel DS, Greipp PR, Rajkumar SV, Fonseca R. Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03. British Journal of Haematology. 155: 340-8. PMID 21902684 DOI: 10.1111/J.1365-2141.2011.08849.X |
0.417 |
|
| 2011 |
Kumar SK, Uno H, Jacobus SJ, Van Wier SA, Ahmann GJ, Henderson KJ, Callander NS, Haug JL, Siegel DS, Greipp PR, Fonseca R, Rajkumar SV. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 118: 4359-62. PMID 21860025 DOI: 10.1182/Blood-2011-03-342089 |
0.382 |
|
| 2011 |
Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: A clash of philosophies Blood. 118: 3205-3211. PMID 21791430 DOI: 10.1182/Blood-2011-06-297853 |
0.312 |
|
| 2011 |
Wadhera RK, Kyle RA, Larson DR, Dispenzieri A, Kumar S, Lazarus HM, Rajkumar SV. Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. Blood. 118: 2985-7. PMID 21765020 DOI: 10.1182/Blood-2011-04-349175 |
0.462 |
|
| 2011 |
Larsen JT, Chee CE, Lust JA, Greipp PR, Rajkumar SV. Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival. Blood. 118: 2702-7. PMID 21750316 DOI: 10.1182/Blood-2011-03-341933 |
0.426 |
|
| 2011 |
Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, ... ... Rajkumar SV, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 118: 2970-5. PMID 21690557 DOI: 10.1182/Blood-2011-04-348896 |
0.341 |
|
| 2011 |
Madan S, Lacy MQ, Dispenzieri A, Gertz MA, Buadi F, Hayman SR, Detweiler-Short K, Dingli D, Zeldenrust S, Lust J, Greipp PR, Rajkumar SV, Kumar S. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood. 118: 1763-5. PMID 21673347 DOI: 10.1182/Blood-2011-04-350009 |
0.419 |
|
| 2011 |
Kumar SK, Lacy MQ, Hayman SR, Stewart K, Buadi FK, Allred J, Laumann K, Greipp PR, Lust JA, Gertz MA, Zeldenrust SR, Bergsagel PL, Reeder CB, Witzig TE, Fonseca R, ... ... Rajkumar SV, et al. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. American Journal of Hematology. 86: 640-5. PMID 21630308 DOI: 10.1002/Ajh.22053 |
0.458 |
|
| 2011 |
Rajkumar SV. Treatment of multiple myeloma Nature Reviews Clinical Oncology. 8: 479-491. PMID 21522124 DOI: 10.1038/Nrclinonc.2011.63 |
0.332 |
|
| 2011 |
Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 117: 6063-73. PMID 21447828 DOI: 10.1182/Blood-2011-02-297325 |
0.404 |
|
| 2011 |
Landgren O, Kyle RA, Rajkumar SV. From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1243-52. PMID 21411440 DOI: 10.1158/1078-0432.Ccr-10-1822 |
0.398 |
|
| 2011 |
Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A, Gertz M, Kumar S, Mikhael J, Roy V, Kyle RA, Lacy MQ. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia. 25: 906-8. PMID 21350560 DOI: 10.1038/leu.2011.29 |
0.347 |
|
| 2011 |
Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Tan T, Sinha S, Leung N, Kyle RA, Rajkumar SV, Gertz MA. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. American Journal of Hematology. 86: 251-5. PMID 21328431 DOI: 10.1002/Ajh.21948 |
0.393 |
|
| 2011 |
Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksaç M, Anderson KC, Moreau P, Singhal S, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 117: 4701-5. PMID 21292778 DOI: 10.1182/Blood-2010-10-299529 |
0.358 |
|
| 2011 |
Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 117: 4691-5. PMID 21292775 DOI: 10.1182/Blood-2010-10-299487 |
0.317 |
|
| 2011 |
San-Miguel JF, Dimopoulos MA, Stadtmauer EA, Rajkumar SV, Siegel D, Bravo ML, Olesnyckyj M, Knight RD, Zeldis JB, Harousseau JL, Weber DM. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clinical Lymphoma, Myeloma & Leukemia. 11: 38-43. PMID 21273172 DOI: 10.3816/Clml.2010.N.120 |
0.43 |
|
| 2011 |
Landgren O, Rajkumar SV. Development of early treatment strategies for high-risk myeloma precursor disease in the future. Seminars in Hematology. 48: 66-72. PMID 21232660 DOI: 10.1053/J.Seminhematol.2010.11.009 |
0.422 |
|
| 2011 |
Kumar SK, Gertz MA, Lacy MQ, Dingli D, Hayman SR, Buadi FK, Short-Detweiler K, Zeldenrust SR, Leung N, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Dispenzieri A. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clinic Proceedings. 86: 12-8. PMID 21193650 DOI: 10.4065/Mcp.2010.0480 |
0.338 |
|
| 2011 |
Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk‐stratification, and management American Journal of Hematology. 86: 57-65. PMID 21181954 DOI: 10.1002/Ajh.21913 |
0.437 |
|
| 2011 |
Siragusa S, Morice W, Gertz MA, Kyle RA, Greipp PR, Lust JA, Witzig TE, Lacy MQ, Zeldenrust SR, Rajkumar SV, Russell SJ, Hayman SR, Buadi F, Kumar SK, Dingli D, et al. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. Annals of Hematology. 90: 101-6. PMID 20645101 DOI: 10.1007/S00277-010-1028-8 |
0.38 |
|
| 2011 |
Gertz MA, Buadi FK, Hayman SR, Dingli D, Dispenzieri A, Greipp PR, Kumar S, Lacy MQ, Lust JA, Leung N, Rajkumar SV, Russell SJ, Zeldenrust SR, Mikhael JR, Roy V, et al. IgD Amyloidosis: An Unrecognized Entity Blood. 118: 5079-5079. DOI: 10.1182/Blood.V118.21.5079.5079 |
0.417 |
|
| 2011 |
Kumar S, Lee JH, Lahuerta JJ, Morgan GJ, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, Leleu X, Hullin C, Klein SK, Sonneveld P, Siegel DS, ... ... Rajkumar SV, et al. Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia, Blood. 118: 3989-3989. DOI: 10.1182/Blood.V118.21.3989.3989 |
0.452 |
|
| 2011 |
Rana V, Srivastava G, Hayman SR, Buadi FK, Gertz MA, Lacy MQ, Greipp PR, Zeldenrust SR, Dispenzieri A, Kyle RA, Lust JA, Short KD, Dingli D, Russell SJ, Rajkumar SV, et al. Factors Predicting Early Mortality in Patients with Newly Diagnosed Multiple Myeloma, Blood. 118: 3981-3981. DOI: 10.1182/Blood.V118.21.3981.3981 |
0.437 |
|
| 2011 |
Lacy MQ, LaPlant BR, Laumann K, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Kumar S, Lust JA, Russell S, Dingli D, Zeldenrust SR, Greipp PR, Fonseca R, Bergsagel P, ... ... Rajkumar SV, et al. Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years, Blood. 118: 3963-3963. DOI: 10.1182/Blood.V118.21.3963.3963 |
0.365 |
|
| 2011 |
Leung N, Bridoux F, Kumar S, Cook M, Rajkumar SV, Ecotiere L, Ludwig H, Hutchison CA. Both Hematologic and Renal Response Affect Overall Survival of Myeloma Patients with Acute Kidney Injury, Blood. 118: 3949-3949. DOI: 10.1182/Blood.V118.21.3949.3949 |
0.381 |
|
| 2011 |
Larsen JT, Kumar S, Rajkumar SV. Serum Free Light Chain Ratio in Distinguishing Smoldering Multiple Myeloma From Active Multiple Myeloma Blood. 118: 3948-3948. DOI: 10.1182/Blood.V118.21.3948.3948 |
0.436 |
|
| 2011 |
Kapoor P, Gertz MA, Rajkumar SV, Lacy MQ, Dingli D, Hayman SR, Russell SJ, Lust JA, Buadi FK, Zeldenrust SR, Greipp PR, Dispenzieri A, Kyle RA, Kumar S. Survival Outcome of Young Multiple Myeloma (MM) Patients in the Era of Novel Therapies Blood. 118: 2950-2950. DOI: 10.1182/Blood.V118.21.2950.2950 |
0.458 |
|
| 2011 |
Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Greipp PR, Witzig TE, Kumar S, Moon-Tasson LL, Rajkumar SV, Donovan KA. Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative Component Blood. 118: 2945-2945. DOI: 10.1182/Blood.V118.21.2945.2945 |
0.373 |
|
| 2011 |
Mikhael JR, Hayman SR, Laumann K, Roy V, LaPlant BR, Kumar S, Buadi FK, Reeder CB, Gertz MA, Dispenzieri A, Lust JA, Stewart AK, Russell S, Bergsagel P, Dingli D, ... ... Rajkumar SV, et al. Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort Blood. 118: 2942-2942. DOI: 10.1182/Blood.V118.21.2942.2942 |
0.408 |
|
| 2011 |
Dispenzieri A, Gertz MA, Saenger AK, Grogan M, Kumar S, Lacy MQ, Kyle RA, Leung N, Zeldenrust S, Hayman SR, Buadi FK, Greipp PR, Rajkumar SV, Russell S, Dingli D, et al. The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis Blood. 118: 2887-2887. DOI: 10.1182/Blood.V118.21.2887.2887 |
0.32 |
|
| 2011 |
Glavey SV, Dispenzieri A, Gertz MA, Kumar S, Lacy MQ, Buadi FK, Rajkumar SV, Hayman SR, Lust JA, Russell SJ, Zeldenrust SR, Dingli D, Hall RL, Leung N. The Depth of Renal Response Strongly Predicts Overall Surival in Patients with AL Amyloidosis Blood. 118: 2868-2868. DOI: 10.1182/Blood.V118.21.2868.2868 |
0.373 |
|
| 2011 |
Harvey RD, Jacobus SJ, Rajkumar SV, Greipp PR, Lonial S. Renal Function Measures Improve on Lenalidomide and Dexamethasone and Compete with Patient Characteristics to Predict Lenalidomide Dose Density and Hematologic Toxicity: An E4A03 Analysis Blood. 118: 1882-1882. DOI: 10.1182/Blood.V118.21.1882.1882 |
0.341 |
|
| 2011 |
Velinova S, Catchatourian R, Kumar S, Rajkumar SV, Greenberg A, Singla S. Racial Disparities in Cytogenetic Characteristics and Outcome of Multiple Myeloma Blood. 118: 1808-1808. DOI: 10.1182/Blood.V118.21.1808.1808 |
0.67 |
|
| 2011 |
Pardanani A, Lasho TL, Finke C, Rajkumar SV, Singh PP, Ketterling RP, Hanson CA, Katzmann JA, Tefferi A. Immunoglobulin Free Light Chain Levels Predict Survival in Primary Myelofibrosis and De Novo Myelodysplastic Syndromes Blood. 118: 1756-1756. DOI: 10.1182/Blood.V118.21.1756.1756 |
0.407 |
|
| 2011 |
Kapoor P, Rajkumar SV. Update on risk stratification and treatment of newly diagnosed multiple myeloma International Journal of Hematology. 1-11. DOI: 10.1007/S12185-011-0947-Z |
0.407 |
|
| 2011 |
Schuster SR, Rajkumar SV, Dispenzieri A, Morice W, Aspitia AM, Ansell S, Kyle R, Mikhael J. The definition of IgM multiple myeloma American Journal of Hematology. 86: 718-719. DOI: 10.1002/Ajh.22080 |
0.316 |
|
| 2010 |
Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Bladé J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL, Richardson PG, ... ... Rajkumar SV, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4976-84. PMID 20956629 DOI: 10.1200/Jco.2010.30.8791 |
0.314 |
|
| 2010 |
Rajkumar SV, Kyle RA, Buadi FK. Advances in the Diagnosis, Classification, Risk Stratification, and Management of Monoclonal Gammopathy of Undetermined Significance: Implications for Recategorizing Disease Entities in the Presence of Evolving Scientific Evidence Mayo Clinic Proceedings. 85: 945-948. PMID 20884827 DOI: 10.4065/Mcp.2010.0520 |
0.342 |
|
| 2010 |
Dispenzieri A, Dingli D, Kumar SK, Rajkumar SV, Lacy MQ, Hayman S, Buadi F, Zeldenrust S, Leung N, Detweiler-Short K, Lust JA, Russell SJ, Kyle RA, Gertz MA. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. American Journal of Hematology. 85: 757-9. PMID 20872958 DOI: 10.1002/Ajh.21822 |
0.359 |
|
| 2010 |
Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, ... ... Rajkumar SV, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 24: 1934-9. PMID 20827286 DOI: 10.1182/Blood.V114.22.429.429 |
0.432 |
|
| 2010 |
Kumar S, Dispenzieri A, Katzmann JA, Larson DR, Colby CL, Lacy MQ, Hayman SR, Buadi FK, Leung N, Zeldenrust SR, Ramirez-Alvarado M, Clark RJ, Kyle RA, Rajkumar SV, Gertz MA. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 116: 5126-9. PMID 20798235 DOI: 10.1182/Blood-2010-06-290668 |
0.38 |
|
| 2010 |
Rajkumar SV. Optimising bortezomib in newly diagnosed multiple myeloma Lancet Oncology. 11: 909-910. PMID 20739219 DOI: 10.1016/S1470-2045(10)70199-6 |
0.341 |
|
| 2010 |
Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, Dispenzieri A, Greipp PR, Habermann TM, Hayman SR, Inwards DJ, ... ... Rajkumar SV, et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clinic Proceedings. 85: 824-33. PMID 20702770 DOI: 10.4065/Mcp.2010.0304 |
0.415 |
|
| 2010 |
Gay F, Rajkumar SV, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ, Chen-Kiang S, Roy V, Jayabalan DS, Lust JA, Witzig TE, et al. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. American Journal of Hematology. 85: 664-9. PMID 20645430 DOI: 10.1002/Ajh.21777 |
0.379 |
|
| 2010 |
Kumar S, Zhang L, Dispenzieri A, Van Wier S, Katzmann JA, Snyder M, Blood E, DeGoey R, Henderson K, Kyle RA, Bradwell AR, Greipp PR, Rajkumar SV, Fonseca R. Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma. Leukemia. 24: 1498-505. PMID 20520636 DOI: 10.1038/Leu.2010.128 |
0.306 |
|
| 2010 |
Stankowski-Drengler T, Gertz MA, Katzmann JA, Lacy MQ, Kumar S, Leung N, Hayman SR, Buadi F, Kyle RA, Rajkumar SV, Dispenzieri A. Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome. American Journal of Hematology. 85: 431-4. PMID 20513121 DOI: 10.1002/Ajh.21707 |
0.36 |
|
| 2010 |
Kapoor P, Fonseca R, Rajkumar SV, Sinha S, Gertz MA, Stewart AK, Bergsagel PL, Lacy MQ, Dingli DD, Ketterling RP, Buadi F, Kyle RA, Witzig TE, Greipp PR, Dispenzieri A, et al. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clinic Proceedings. 85: 532-7. PMID 20511484 DOI: 10.4065/Mcp.2009.0677 |
0.421 |
|
| 2010 |
Bianchi G, Kyle RA, Colby CL, Larson DR, Kumar S, Katzmann JA, Dispenzieri A, Therneau TM, Cerhan JR, Melton LJ, Rajkumar SV. Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. Blood. 116: 2019-25; quiz 2197. PMID 20495076 DOI: 10.1182/Blood-2010-04-277566 |
0.389 |
|
| 2010 |
Dingli D, Rajkumar SV. How best to use new therapies in multiple myeloma. Blood Reviews. 24: 91-100. PMID 20359801 DOI: 10.1016/J.Blre.2010.03.001 |
0.336 |
|
| 2010 |
Palumbo A, Rajkumar SV. Multiple myeloma: Chemotherapy or transplantation in the era of new drugs European Journal of Haematology. 84: 379-390. PMID 20345446 DOI: 10.1111/J.1600-0609.2010.01431.X |
0.41 |
|
| 2010 |
Madan S, Dispenzieri A, Lacy MQ, Buadi F, Hayman SR, Zeldenrust SR, Rajkumar SV, Gertz MA, Kumar SK. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clinic Proceedings. 85: 232-8. PMID 20194151 DOI: 10.1182/Blood.V114.22.4867.4867 |
0.361 |
|
| 2010 |
Ansell SM, Rajkumar SV. Hematology: Trials and tribulations in primary CNS lymphoma. Nature Reviews. Clinical Oncology. 7: 125-6. PMID 20190791 DOI: 10.1038/Nrclinonc.2010.9 |
0.395 |
|
| 2010 |
Ludwig H, Bolejack V, Crowley J, Bladé J, Miguel JS, Kyle RA, Rajkumar SV, Shimizu K, Turesson I, Westin J, Sonneveld P, Cavo M, Boccadoro M, Palumbo A, Tosi P, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1599-605. PMID 20177027 DOI: 10.1200/Jco.2009.25.2114 |
0.359 |
|
| 2010 |
Landgren O, Goedert JJ, Rabkin CS, Wilson WH, Dunleavy K, Kyle RA, Katzmann JA, Rajkumar SV, Engels EA. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 773-9. PMID 20048176 DOI: 10.1200/Jco.2009.25.1322 |
0.324 |
|
| 2010 |
Bladé J, Dimopoulos M, Rosiñol L, Rajkumar SV, Kyle RA. Smoldering (Asymptomatic) Multiple Myeloma: Current Diagnostic Criteria, New Predictors of Outcome, and Follow-Up Recommendations Journal of Clinical Oncology. 28: 690-697. PMID 20026810 DOI: 10.1200/Jco.2009.22.2257 |
0.406 |
|
| 2010 |
Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, Kumar S, Dispenzieri A, Mikhael JR, Bergsagel PL, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, ... ... Rajkumar SV, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood. 115: 1343-50. PMID 20008302 DOI: 10.1182/Blood-2009-08-239046 |
0.421 |
|
| 2010 |
Sinha S, Rajkumar SV, Lacy MQ, Hayman SR, Buadi FK, Dispenzieri A, Dingli D, Kyle RA, Gertz MA, Kumar S. Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma. British Journal of Haematology. 148: 853-8. PMID 19958361 DOI: 10.1111/J.1365-2141.2009.08023.X |
0.452 |
|
| 2010 |
Schaefer EW, Kumar S, Dispenzieri A, Allred JB, Gertz MA, Lacy MQ, Rajkumar SV, Mandrekar SJ. Residual serum monoclonal protein predicts progression-free survival in patients with previously untreated multiple myeloma. Cancer. 116: 640-6. PMID 19924791 DOI: 10.1002/Cncr.24767 |
0.331 |
|
| 2010 |
Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M, Greipp PR. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. The Lancet. Oncology. 11: 29-37. PMID 19853510 DOI: 10.1016/S1470-2045(09)70284-0 |
0.363 |
|
| 2010 |
Kyle RA, Rajkumar SV. Treatment of multiple myeloma: a comprehensive review. Clinical Lymphoma & Myeloma. 9: 278-88. PMID 19717377 DOI: 10.3816/Clm.2009.N.056 |
0.463 |
|
| 2010 |
Dingli D, Buadi F, Dispenzieri A, Hayman S, Kumar S, Lacy M, Russell S, Rajkumar SV, Gertz MA. Depth of response with stem cell transplantation and outcome for multiple myeloma in the era of novel agents F1000research. 1. DOI: 10.7490/F1000Research.140.1 |
0.302 |
|
| 2010 |
Dispenzieri A, Gertz MAA, Hayman SR, Buadi F, Kumar S, Reeder CB, Mikhael JR, Zeldenrust S, Rajkumar SV, Detweiler-Short K, Greipp PR, Russell SJ, Dingli D, Allred J, Laumann K, et al. A Phase-2 Study of Pomalidomide and Dexamethasone In Previously-Treated Light-Chain (AL) Amyloidosis Blood. 116: 987-987. DOI: 10.1182/Blood.V116.21.987.987 |
0.348 |
|
| 2010 |
Kumar S, Flinn IW, Richardson PG, Hari P, Callander NS, Noga SJ, Stewart AK, Glass J, Rifkin RM, Wolf JL, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV. Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study Blood. 116: 621-621. DOI: 10.1182/Blood.V116.21.621.621 |
0.42 |
|
| 2010 |
Ramakrishnan VG, Kimlinger T, Haug J, Halling T, Wellik L, Rajkumar SV, Kumar S. Mechanism of Action of a Novel c-Met Inhibitor MK2461 In Multiple Myeloma Blood. 116: 4078-4078. DOI: 10.1182/Blood.V116.21.4078.4078 |
0.344 |
|
| 2010 |
Larsen JT, Chee CE, Lust J, Greipp PR, Rajkumar SV. Reduction In Proliferative Rate of Myeloma Plasma Cells Measured by the Plasma Cell Labeling Index Predicts Improved Survival In Multiple Myeloma Blood. 116: 4048-4048. DOI: 10.1182/Blood.V116.21.4048.4048 |
0.457 |
|
| 2010 |
Dispenzieri A, Kyle R, Katzmann JA, Larson D, Kumar S, Mead GP, Bradwell A, Rajkumar SV. Non-Clonal Serum Immunoglobulin Free Light Chains (FLC) as Markers of Overall Survival Blood. 116: 3893-3893. DOI: 10.1182/Blood.V116.21.3893.3893 |
0.38 |
|
| 2010 |
Siegel DSd, Jacobus S, Rajkumar SV, Abonour R, Callander NS, Katz MS, Fonseca R, Vesole DH, Group ObotECO. Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial Blood. 116: 38-38. DOI: 10.1182/Blood.V116.21.38.38 |
0.418 |
|
| 2010 |
Madan S, Kumar S, Lacy M, Dispenzieri A, Buadi F, Hayman SR, Dingli D, Rajkumar SV, Gertz M. Pre-Stem Cell Transplant Induction Therapy Does Not Affect Post-Transplant Survival In Light Chain (AL) Amyloidosis Blood. 116: 370-370. DOI: 10.1182/Blood.V116.21.370.370 |
0.407 |
|
| 2010 |
Vesole DH, Jacobus S, Rajkumar SV, Abonour R, Callander NS, Greipp PR, Fonseca R, Katz MS, Siegel DSd. Lenalidomide Plus Low-Dose Dexamethasone (Ld): Superior One and Two Year Survival Regardless of Age Compared to Lenalidomide Plus High-Dose Dexamethasone (LD) Blood. 116: 308-308. DOI: 10.1182/Blood.V116.21.308.308 |
0.383 |
|
| 2010 |
Witzig TE, Mandrekar S, Detweiler-Short K, Lacy MQ, Laumann K, Dispenzieri A, Hayman SR, Kumar S, Reeder CB, Roy V, Lust JA, Gertz MA, Greipp PR, Rajkumar SV. A Phase III Randomized Trial of Thalidomide (THAL) Plus Zoledronic Acid (ZLD) Versus Zoledronic Acid Alone In Patients with Early Stage Multiple Myeloma (MC0289) Blood. 116: 3053-3053. DOI: 10.1182/Blood.V116.21.3053.3053 |
0.475 |
|
| 2010 |
Short KD, Rajkumar SV, Buadi F, Larson D, Hayman SR, Dispenzieri A, Gertz MAA, Kumar S, Mikhael JR, Roy V, Kyle R, Lacy M. Increased Incidence of Extramedullary Plasmacytomas In Patients with Multiple Myeloma In the Era of Novel Therapy and Effect of Pomalidomide on Extramedullary Disease Blood. 116: 3047-3047. DOI: 10.1182/Blood.V116.21.3047.3047 |
0.478 |
|
| 2010 |
Bianchi G, Ramakrishnan VG, Kimlinger T, Haug J, Rajkumar SV, Kumar S. Investigational Agent MLN2238/MLN9708, a Specific, Orally Available, Small Molecule Proteasome Inhibitor, Shows Promising In Vitro Activity Against Multiple Myeloma Cell Lines Blood. 116: 3014-3014. DOI: 10.1182/Blood.V116.21.3014.3014 |
0.365 |
|
| 2010 |
Haug J, Ramakrishnan VG, Kimlinger T, Halling T, Wellik L, Rajkumar SV, Kumar S. Significant In Vitro Activity of a Novel Inhibitor of Apoptosis (IAP) Inhibitor LC161 In Multiple Myeloma Blood. 116: 2998-2998. DOI: 10.1182/Blood.V116.21.2998.2998 |
0.338 |
|
| 2010 |
Sinha S, Gertz M, Lacy M, Dispenzieri A, Hayman S, Buadi F, Dingli D, Micallef I, Hogan W, Gastineau D, Rajkumar SV, Kumar S. Peripheral Blood Stem Cell Collection In Patients Undergoing Induction Therapy with Lenalidomide Based Regimens: Failure Rates and Salvage Approaches Blood. 116: 2253-2253. DOI: 10.1182/Blood.V116.21.2253.2253 |
0.39 |
|
| 2010 |
Madan S, Lacy M, Dispenzieri A, Gertz M, Buadi F, Hayman SR, Detweiler-Short K, Dingli D, Zeldenrust S, Lust J, Greipp PR, Rajkumar SV, Kumar S. Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma Blood. 116: 1964-1964. DOI: 10.1182/Blood.V116.21.1964.1964 |
0.422 |
|
| 2010 |
Chee CE, Rajkumar SV, Gertz MAA, Lacy M, Zeldenrust S, Kumar S, Hayman SR, Buadi F, Russell S, Kyle R, Greipp PR, Dispenzieri A. Higher Plasma Cell Burden Predicts for Early Death In Patients with AL Amyloidosis Blood. 116: 1893-1893. DOI: 10.1182/Blood.V116.21.1893.1893 |
0.423 |
|
| 2010 |
Ramakrishnan V, Haug J, Kimlinger T, Halling T, Wellik L, Rajkumar SV, Kumar S. Abstract 1796: Significant in-vitro anti-myeloma activity of a novel Akt inhibitor MK2206 Cancer Research. 70: 1796-1796. DOI: 10.1158/1538-7445.Am10-1796 |
0.321 |
|
| 2009 |
Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Greipp PR, Hayman SR, Kyle RA, Lacy MQ, Lust JA, Reeder CB, Roy V, Russell SJ, ... ... Rajkumar SV, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clinic Proceedings. 84: 1095-110. PMID 19955246 DOI: 10.4065/Mcp.2009.0603 |
0.373 |
|
| 2009 |
Lacy MQ, Mandrekar S, Dispenzieri A, Hayman S, Kumar S, Buadi F, Dingli D, Litzow M, Wettstein P, Padley D, Kabat B, Gastineau D, Rajkumar SV, Gertz MA. Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. American Journal of Hematology. 84: 799-802. PMID 19899131 DOI: 10.1002/Ajh.21560 |
0.397 |
|
| 2009 |
Tsai HT, Caporaso NE, Kyle RA, Katzmann JA, Dispenzieri A, Hayes RB, Marti GE, Albitar M, Ghia P, Rajkumar SV, Landgren O. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood. 114: 4928-32. PMID 19828698 DOI: 10.1182/Blood-2009-08-237651 |
0.346 |
|
| 2009 |
Rajkumar SV. Prevention of progression in monoclonal gammopathy of undetermined significance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5606-8. PMID 19737944 DOI: 10.1158/1078-0432.Ccr-09-1575 |
0.369 |
|
| 2009 |
Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, ... ... Rajkumar SV, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5008-14. PMID 19720894 DOI: 10.1200/Jco.2009.23.6802 |
0.33 |
|
| 2009 |
Bida JP, Kyle RA, Therneau TM, Melton LJ, Plevak MF, Larson DR, Dispenzieri A, Katzmann JA, Rajkumar SV. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clinic Proceedings. 84: 685-93. PMID 19648385 DOI: 10.4065/84.8.685 |
0.332 |
|
| 2009 |
Chee CE, Kumar S, Larson DR, Kyle RA, Dispenzieri A, Gertz MA, Colby CL, Rajkumar SV. The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. Blood. 114: 2617-8. PMID 19641191 DOI: 10.1182/Blood-2009-01-198788 |
0.402 |
|
| 2009 |
Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Lentzsch S, Munshi N, Niesvizky R, San Miguel J, Ludwig H, Bergsagel L, Blade J, Lonial S, ... ... Rajkumar SV, et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 114: 1729-35. PMID 19561323 DOI: 10.1182/Blood-2009-04-205013 |
0.363 |
|
| 2009 |
Gertz MA, Leung N, Lacy MQ, Dispenzieri A, Zeldenrust SR, Hayman SR, Buadi FK, Dingli D, Greipp PR, Kumar SK, Lust JA, Rajkumar SV, Russell SJ, Witzig TE. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 24: 3132-7. PMID 19403931 DOI: 10.1093/ndt/gfp201 |
0.307 |
|
| 2009 |
Rajkumar SV, Sonneveld P. Front-Line Treatment in Younger Patients With Multiple Myeloma Seminars in Hematology. 46: 118-126. PMID 19389495 DOI: 10.1053/J.Seminhematol.2009.02.005 |
0.384 |
|
| 2009 |
Ashrani AA, Rajkumar SV. Chemotherapy-Associated Thrombosis Cancer Treatment and Research. 148: 181-206. PMID 19377925 DOI: 10.1007/978-0-387-79962-9_11 |
0.378 |
|
| 2009 |
Kyle RA, Benson J, Larson D, Therneau T, Dispenzieri A, Melton Iii LJ, Rajkumar SV. IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia. Clinical Lymphoma & Myeloma. 9: 17-8. PMID 19362962 DOI: 10.3816/Clm.2009.N.002 |
0.368 |
|
| 2009 |
Braggio E, Keats JJ, Leleu X, Van Wier S, Jimenez-Zepeda VH, Valdez R, Schop RF, Price-Troska T, Henderson K, Sacco A, Azab F, Greipp P, Gertz M, Hayman S, Rajkumar SV, et al. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Research. 69: 3579-88. PMID 19351844 DOI: 10.1158/0008-5472.Can-08-3701 |
0.3 |
|
| 2009 |
Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, Dispenzieri A, Buadi F, Bergsagel PL, Gertz MA, Dalton RJ, Mikhael JR, Dingli D, Reeder CB, Lust JA, ... ... Rajkumar SV, et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 114: 518-21. PMID 19324902 DOI: 10.1182/Blood-2009-01-202010 |
0.441 |
|
| 2009 |
Lacy MQ, Jacobus S, Blood EA, Kay NE, Rajkumar SV, Greipp PR. Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group. Leukemia Research. 33: 1485-9. PMID 19243818 DOI: 10.1016/J.Leukres.2009.01.020 |
0.312 |
|
| 2009 |
Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S, Kumar S, Hayman S, Buadi F, Kyle RA, Greipp PR, Lust JA, Russell S, Rajkumar SV, Fonseca R, et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica. 94: 380-6. PMID 19211640 DOI: 10.3324/Haematol.13369 |
0.348 |
|
| 2009 |
Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, Kumar S, Hayman SR, Russell SJ, Buadi FK, Geyer SM, Campbell ME, Kyle RA, Rajkumar SV, Greipp PR, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clinic Proceedings. 84: 114-22. PMID 19181644 DOI: 10.4065/84.2.114 |
0.327 |
|
| 2009 |
Vachon CM, Kyle RA, Therneau TM, Foreman BJ, Larson DR, Colby CL, Phelps TK, Dispenzieri A, Kumar SK, Katzmann JA, Rajkumar SV. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood. 114: 785-90. PMID 19179466 DOI: 10.1182/Blood-2008-12-192575 |
0.35 |
|
| 2009 |
Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, Hoover R, Rajkumar SV. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 113: 5412-7. PMID 19179464 DOI: 10.1182/Blood-2008-12-194241 |
0.372 |
|
| 2009 |
Drake MT, Rajkumar SV. Effects of bortezomib on bone disease in multiple myeloma. American Journal of Hematology. 84: 1-2. PMID 19030185 DOI: 10.1002/Ajh.21324 |
0.318 |
|
| 2009 |
Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma Leukemia. 23: 449-456. PMID 19005483 DOI: 10.1038/leu.2008.325 |
0.371 |
|
| Show low-probability matches. |